Prevention of cardiovascular disease and diabetes on a population level by Gyberg, Viveca
The Karolinska Institutet, Department of MedicineCardiology Unit, Karolinska University HospitalStockholm, Sweden
Prevention of Cardiovascular Disease and Diabetes on a Population LevelbyViveca Gyberg
Stockholm 2014
The cover figure is reprinted with permission from Shutterstock.All previously published papers are reproduced with permission from the publisher.Published and printed by TMG Sthlm ABViveca Gyberg, 2014ISBN 978-91-7549-578-1
To my loved ones
“Energy cannot be created or destroyed, 
it can only be changed from one form to another.”- Albert Einstein
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ABSTRACT
BackgroundCardiovascular disease and diabetes are responsible for just over half of the global mortality, 
and these diseases are expected to increase. The upsurge is due to increased longevity and a 
westernisation of the global lifestyle. Preventive efforts have proven effective and are believed 
to be the only way to curb the rapid increase of these diseases. Still the implementations of 
preventive measures are reported as underused.
Aims To study prevention by
1. Investigating the perception of key policymakers on cardiovascular disease 
2. Examining if screening for diabetes online is feasible using FINDRISC
3. Assessing management of patients with coronary artery disease and diabetes 
4. Determining the best screening test for dysglycaemia in patients with coronary artery disease
Policymakers’ perception of cardiovascular disease Policymakers in Europe agreed that national patterns of cardiovascular disease and its 
prevention are far from satisfactory. A similar rating of the perceived proximity to a specific 
target in two countries did not necessarily reflect a similar national situation when compared to 
available statistics on the actual situation. Policymakers had diverging opinions on what actions 
to take and what obstacles to overcome to improve population health.
Feasibility of using FINDRISC as an online questionnaire 
It was feasible to incorporate a diabetes risk score such as FINDRISC in an online survey. 
A reasonable response rate was achieved and a group that could benefit from preventive 
intervention programs was identified.
Management of patients with coronary artery disease and diabetesA large proportion of the patients are far from guideline recommended evidence based treatment 
targets for blood pressure, LDL-cholesterol and HbA1c. A potential reason is a consistent, relatively low combined use of four selected cardioprotective drug therapies and/or lack of dose 
titration. There was, however, some improvement over time.
Screening for dysglycaemia in patients with coronary artery disease
Screening by means of an oral glucose tolerance test (OGTT) identified the largest number 
of patients with undetected diabetes. The overlap in case-detection between fasting plasma 
glucose (FPG), 2-hour plasma glucose (2hPG) and HbA1c was small. Screening with HbA1c 
alone would have left 83% of those with diabetes undetected. The total proportion of patients 
identified with diabetes and other forms of dysglycaemia varied from 90% using the American Diabetes Association’s criteria for FPG + HbA1c, which may be an overestimate, to 73% using 
WHO criteria for OGTT = FPG + 2hPG, which may be more realistic.
Conclusion Creating a coherent knowledge base and action agenda regarding prevention among key 
policymakers should be given high priority in future population based prevention programmes. The online questionnaire FINDRISC is a feasible way to identify high-risk individuals as well 
as risk typing populations. Despite some improvement, patients with coronary artery disease 
and diabetes are not managed according to best available knowledge. Efforts to improve this 
are needed to improve their still dismal prognosis. An oral glucose tolerance test has the best 
capacity to screen-detect dysglycaemia in patients with coronary artery disease. 
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SAMMANFATTNING
BakgrundHjärt-kärlsjukdom och diabetes står för drygt hälften av alla dödsfall globalt och dessa 
sjukdomar väntas öka. Ökningen beror framför allt på en allt längre livslängd och vår moderna 
livsstil med brist på fysisk aktivitet och för högt kaloriintag. Det är välkänt att förebyggande 
åtgärder och behandling kan minska eller senarelägga insjuknandet i dessa sjukdomar. Trots 
denna kunskap rapporteras det ofta om ett bristfälligt genomförande av förebyggande insatser.
MålAtt studera prevention genom att
1. Undersöka beslutsfattares uppfattning om kardiovaskulär sjukdom 
2. Studera screening för diabetes på internet med hjälp av FINDRISC 
3. Utvärdera vården av patienter med kranskärlssjukdom och diabetes 
4. Identifiera det bästa testet för dysglykemi hos patienter med kranskärlssjukdom 
Beslutsfattares uppfattning om kardiovaskulär sjukdomBeslutsfattare i Europa är överens om att deras länder är långt ifrån att uppnå önskvärda 
hälsomål. Då två länders beslutsfattare uppfattade den nationella förekomsten av ohälsosamma faktorer eller vidtagna hälso-befrämjande åtgärder lika, överensstämde ofta inte deras 
respektive situationer baserat på tillgängliga data från epidemiologiska undersökningar. Beslutsfattarna hade olika uppfattningar om vilka initiativ som var viktigast för att förbättra 
befolkningens hälsa. 
Screening för diabetes på internet med hjälp av FINDRISC
FINDRISC-frågorna kunde infogas i ett internetbaserat frågeformulär. Svarsfrekvensen var 
rimligt god och en grupp som kunde dra nytta av prevention identifierades.
Vård av patienter med kranskärlssjukdom och diabetesEn stor andel av patienter med kranskärlssjukdom och diabetes når inte de i riktlinjer angivna 
målen för blodtryck, LDL-kolesterol och HbA1c. En sannolik förklaring är att tillgängliga 
läkemedel inte kombineras eller doseras helt ändamålsenligt. Över tid har vården av dessa 
patienter förbättrats, trots bestående brister.
Dysglykemi-test hos patienter med kranskärlssjukdom  
Ett oralt glukostoleranstest identifierar den största andelen av patienter med diabetes. 
Överenstämmelsen mellan plasmaglukos fastande (FPG) eller efter glukosbelastning (2hPG) 
och HbA1c för patienter som screenades med diabetes var liten. Screening med enbart HbA1c 
skulle lämnat 83% av patienterna med diabetes oupptäckta. Enligt kriterier angivna av American Diabetes Association för FPG + HbA1c hade 90% av patienterna dysglykemi jämfört 
med 73% med WHO:s kriterier för glukosbelastning. Den förra proportionen uppfattas som en 
överskattning och den senare som mer realistisk.
SlutsatsAtt tydliggöra aktuella epidemiologiska data och information över vidtagna åtgärder måste ges högsta prioritet för att skapa samsyn mellan beslutsfattare och förbättra effekten av framtida 
preventiva initiativ. Genom att screena för diabetes på internet med hjälp av FINDRISC kunde 
såväl individer som en befolkningsgrupps risk kartläggas. Även om läget har förbättrats är patienter med kranskärlssjukdom och diabetes en grupp vars handläggning ännu inte 
uppnår uppsatta riktlinjebaserade behandlingsmål. Ur prognostisk synvinkel är en förbättring 
önskvärd med hänsyn till gruppens dåliga prognos. Ett oralt glukostoleranstest har den högsta 
tillförlitligheten vid screening för dysglykemi hos patienter med kranskärlssjukdom.
Viveca Gyberg
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INTRODUCTION
Pathophysiology of Cardiovascular Disease & Diabetes
Cardiovascular disease
Cardiovascular disease is a chronic condition commonly defined as atherosclerosis in 
the arteries of the heart, brain and limbs.1 Atherosclerosis is a chronic inflammatory disorder that develops in the arterial walls over many decades as illustrated in Figure 
1.2, 3 This process can be triggered by a wide range of conditions such as hyperglycaemia, 
hyperlipidaemia and hypertension.2 A thickening of the arterial wall occurs due to an accumulation of low density lipoprotein-cholesterol (LDL-cholesterol) in combination 
with a gradually increasing accumulation of inflammatory cells, smooth muscle cells 
and connective tissue. This process was originally believed to be localized but is now 
known to be generally spread throughout the arterial tree.2 Atherosclerosis stiffens the vessel wall and can potentially cause plaque formation, which may limit blood 
flow due to luminal obstruction, possibly leading to ischemia in the supplied tissues. The atherosclerotic plaque may become unstable and rupture activating platelet 
accumulation, which triggers thrombus formation. This may lead to an acute blockage of the artery causing a myocardial infarction if in the coronary arteries, and ischemic 
stroke if in the cerebral arteries.3, 4  
Development of atherosclerosis
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Figure 1. Development of atherosclerosis.
(By permission from Professor J Perk, who adopted it from Stary et al 3).
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Diabetes
Definition and classification
Diabetes, like cardiovascular disease is a chronic condition, and is defined by elevated 
blood glucose due to decreased sensitivity to and/or decreased production of insulin.5, 6 The National Diabetes Data Group issued the first unified classification of diabetes in 19797 followed by the World Health Organization (WHO) in 19808. The classification also includes early stages of hyperglycaemia: impaired fasting glucose (IFG) and impaired 
glucose tolerance (IGT), reflecting the natural history of relative or absolute insulin 
deficiency progressing from normoglycaemia to diabetes as presented in Figure 2. Current diagnostic criteria (Table 1) have been issued by WHO9, 10 and the American Diabetes Association (ADA)11, 12. The WHO recommendations are based on measuring both fasting plasma glucose (FPG) and two-hour post load plasma glucose (2hPG) 
concentrations and recommend that a standardized Oral Glucose Tolerance Test (OGTT) 
should be performed in the absence of overt hyperglycaemia.13 Classification according to the ADA criteria encourages the use of glycated hemoglobin A1c (HbA1c), FPG and 2hPG 
in that order.12 Both ADA and WHO approve a diabetes diagnosis based on symptoms 
such as polyuria together with an elevated random plasma glucose (RPG).12, 14 The thresholds for diabetes for all methods are primarily determined by the cut-off where 
the prevalence of diabetic retinopathy, a specific complication of hyperglycaemia, starts 
to increase.6 Although macrovascular diseases such as coronary artery disease and stroke are major causes of death in patients with type 2 diabetes and individuals with IGT, the 
risk for future macrovascular disease is not considered in this diagnostic classification. The diagnostic criteria adopted by WHO and ADA for prediabetes are similar for IGT but 
differ for IFG. Only ADA uses high risk HbA1c as seen in Table 1. The lower ADA threshold 
for IFG and the use of high risk HbA1c is not adopted by WHO. This is due to a belief in lack 
of evidence of benefits in terms of reducing progression to diabetes and cardiovascular 
events.10, 13
Figure 2. Development of diabetes mellitus type 2.
(By permission from Laakkso et al 15).
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Categories 
Diabetes may be classified as belonging to one of four main etiological categories: type 1, 
type 2, gestational and other specific types 5, 7, 16 
Diabetes type 1 is an autoimmune disorder affecting the insulin producing β-cells of the 
pancreas. Usually it has an abrupt onset with thirst, polyuria and weight loss. The future 
survival depends on insulin treatment.16, 17 Diabetes type 1 most frequently afflicts young 
individuals but may occur at all stages of life.17 A subgroup of diabetes type 1 named latent autoimmune diabetes mellitus in adults (LADA) has a slow onset over a couple of years in 
adulthood.17
Diabetes type 2 is in its early stages characterized by an increased insulin resistance, but 
as the disease progresses insulin secretion becomes compromised as well.16 The onset is 
often slow and the condition can remain undiagnosed for many years. This type of diabetes, which usually occurs in adulthood, is strongly associated with overweight and low physical 
activity.16 It often coexists with other metabolic malfunctions such as high blood pressure 
and hyperlipidaemia.18 This is the most common form of diabetes, comprising 85-95% 
of all diabetes in high-income countries and likely even more in the rest of the world.16, 17 
Diabetes type 2 is in focus of this thesis and will be referred to as diabetes.
Gestational diabetes is caused by a combination of increased resistance to- and demand for 
insulin that develops during pregnancy. Dysglycaemia is estimated to have been present 
in 17% of all live births globally during 2013.16 It usually vanishes after delivery but about 20% of women with this form of diabetes progress to type 2 diabetes during the following 
decades.16
Other specific types of diabetes include genetic mutations leading to rare forms of diabetes such as maturity-onset diabetes in the young and secondary diabetes due to drugs or 
pancreatic disease.17
Prediabetes is a condition characterised by glucose values ranging between normal levels 
and what has been defined as the cut off for diabetes. People with prediabetes are at a 
Table 1. Comparison of the WHO10, 14 and ADA12 diagnostic criteria for dysglycaemia. All tests have 
to be repeated twice except RPG when symptoms are present. Bold indicates preferred tests.
Diagnose/
measurement
WHO14, 10      ADA12
Diabetes   
     HbA1c ≥6.5% ( ≥48 mmol/mol) ≥6.5% (≥48 mmol/mol)
     FPG ≥7.0 mmol/L (≥126 mg/dL) ≥7.0 mmol/L (≥126 mg/dL)
     2hPG ≥11.1 mmol/L (≥200 mg/dL) ≥11.1 mmol/L (≥200 mg/dL)
     RPG Symptoms + ≥11.1 mmol/L (≥200 mg/dL) Symptoms + ≥11.1 mmol/L (≥200 mg/dL)
IGT   
     FPG <7.0 mmol/L (<126 mg/dL) <7.0 mmol/L (<126 mg/dL)
     2hPG ≥7.8 -11.0 mmol/L (≥140-199 mg/dL) ≥7.8 -11.0 mmol/L (≥140-199 mg/dL)
IFG   
     FPG 6.1-6.9 mmol/L (110-125 mg/dL) 5.6-6.9 mmol/L (100-125 mg/dL)
     2hPG <7.8 mmol/L (<140 mg/dL) <7.8 mmol/L (<140 mg/dL)
High Risk HbA1c - 5.7-6.4% (39-47 mmol/mol) 
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high risk for future type 2 diabetes and this condition is also linked to an enhanced risk 
for cardiovascular disease.16 It is estimated that the annual proportion of people with IGT that progress to diabetes is 5-10% and that 90% have diabetes after 20 years without 
intervention.19, 20
Complications to diabetesDiabetes can if uncontrolled lead to serious health problems due to microvascular complications such as retinopathy (causing blindness), nephropathy (causing renal 
failure) and neuropathy (causing autonomic dysfunction and paraesthesia). The most 
common cause of death in patients with diabetes is, however, cardiovascular disease.16, 17 While manifest microvascular complications often develop during one or several decades with elevated blood glucose, the risk for cardiovascular disease is often present already 
before the diagnosis of diabetes is made as illustrated in Figure 2. Potential reasons are 
further elaborated on below.
The link between cardiovascular disease and diabetes Taken together cardiovascular disease and diabetes account for more than half of the global 
mortality.21 These two conditions are closely interlinked with at least half of all patients 
with diabetes dying, often prematurely, of cardiovascular disease.22, 23 Furthermore, 30% of patients with coronary artery disease have diabetes and an additional 35-40% have 
prediabetes leaving only about one third with a normal glucose metabolism.23-25 Moreover, patients with a combination of coronary artery disease and diabetes have a two times higher mortality than those without diabetes, making them a group at particularly high 
risk for a recurrent cardiovascular event or death.26, 27The reason for the increased risk for cardiovascular disease in patients with diabetes is not fully understood, but diabetes has been proven to stimulate the development of 
multiple disadvantageous changes in the arterial wall.15 It involves endothelial dysfunction, 
increased inflammatory activation, enhanced capability for thrombus development and 
decreased thrombolytic ability, all factors that lead to accelerated artheriosclerosis.18 Insulin resistance is known to make the lipid distribution unfavourable, which increases 
lipid accumulation in the vessel walls. In addition LDL-cholesterol in patients with 
diabetes have an enhanced propensity to oxidize, leading to an inflammatory response 
and inhibition of production of vasodilatory nitric oxide.15 Furthermore, vasodilatation is inhibited by increased presence of vasoconstriction due to a disproportionate dominance 
of the sympathetic nervous system. This relates to a hampered vagal nerve activity by autonomic dysfunction, which also contributes to a somewhat high heart rate and blunted 
diurnal variation of blood pressure and heart rate.15 In addition, vasoconstrictors, such 
as endothelin-I and angiotensin II, increase.15 High glucose concentration on its own is 
believed to damage the vascular wall perhaps by inducing an intensified oxidative stress 
that becomes a substrate for endothelial dysfunction.18 Even though there is a continuous relationship between glucose levels and cardiovascular disease very few trials that attempted to decrease cardiovascular outcomes by means of strict glycaemic control have 
managed to do so.28 Epigenetic changes are also believed to prompt processes causing the early rise in cardiovascular risk that also persist with adequate risk factor control, this is 
often referred to as glycaemic memory.29 As of today, and beyond lifestyle adjustments, control of dyslipidaemia and blood pressure are the most effective treatments to prevent 
cardiovascular disease in individuals with diabetes.30
Viveca Gyberg
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Epidemiology of Cardiovascular Disease and Diabetes
An epidemiological transitionDuring the last century there has been an epidemiological transition from morbidity and mortality dominated by infections and malnutritional conditions towards lifestyle ori-
ented illness.31 This first epidemiological transition, is often referred to as a shift from 
communicable to non-communicable diseases. The transition started in high- and mid-
dle-income countries and is now on going in low income parts of the world. Today non-
communicable diseases are responsible for approximately 65% of global mortality.21, 31 
Out of these deaths cardiovascular disease account for 48% and diabetes specific causes 
3,5%.21 This transition has been made possible due to remarkable improvements in living conditions, initiatives to battle hunger, improved management of infections and better 
maternal care.31 This change has led to a rise in global life expectancy from 48 years in 
1950-1955 to 68 years in 2005-2010.31 In areas with the longest life expectancy a current decline of premature deaths of non-communicable disease can be seen, which contributes 
to an even longer life expectancy. The prolongation of life is considered a second epide-
miological transition.31 This indicates what health care challenges lies ahead of us as more 
countries enter the second transition.
Changing risk factor patternsAn older global population is in itself an important risk factor for both cardiovascular 
disease and diabetes but cannot solely explain their increasing prevalence.16, 31, 32 The proportions of causes of death divided by age groups are presented in Figure 3. Societal 
changes such as industrialisation, urbanization, the IT-revolution and the expanding use 
Figure 3. Distribution of causes of death by age groups. Group I includes: communicable diseases as 
well as maternal, perinatal and nutritional conditions, Group II: non-communicable diseases, Group 
III: death resulting from intentional and unintentional injuries. 
(From: Changing Levels and Trends in Mortality: the role of patterns of death by cause (United Nations publication, 
ST/ESA/SER.A/318). United Nations, Department of Economic and Social Affairs, Population Division, © 2012 
United Nations. Reprinted with the permission of the United Nations).
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of processed (fast) food have increased exposure to unhealthy diet, physical inactivity and 
tobacco use.21 This lifestyle has led to an increase of risk factors such as overweight and 
obesity, hypertension, hyperlipidaemia and abnormal glucose metabolism.21 Risk factors are more likely to accumulate with age, and if several risk factors are present the risk for 
cardiovascular disease is multiplied.31, 32 Although cardiovascular disease and diabetes are often diseases of the elderly it should be underlined that cardiovascular illness causes 
31% of deaths in men and 26% in women before the age of 65 in Europe.33 Moreover about 50% of the people with diabetes are 40-59 years old16 and half of the diabetes-
related mortality occurs before the age of 60 years.16
Risk factors for cardiovascular diseaseINTERHEART, a case-control study of about 14 000 people with acute myocardial infarction and a similar number of controls from all continents, showed that more than 90% of all events could be explained by nine factors, the same in men and women: abnormal blood lipids, smoking, hypertension, diabetes, abdominal obesity, poor psychosocial conditions 
and lack of regular physical activity. In contrast regular intake of fruit and vegetables and 
modest alcohol consumption decreased the risk.32 Genetic susceptibilities to myocardial infarction was also analysed but could only explain one additional per cent of the 
population attributable risk when added to the nine risk factors.32 Analyses applying the by Capewell et al34 introduced IMPACT model, combining data on time trends in risk factor patterns with the effect of medical and surgical treatment, in populations with increasing or decreasing cardiovascular mortality underline 
the importance of lifestyle changes.35, 36 In the Chinese capital Beijing cardiovascular mortality increased from 1984 to 1999 by 50% in men and 27% in women primarily due to an increase in the prevalence of high cholesterol and diabetes in the population 
(Figure 4).35 In USA a declining age-standardised cardiovascular mortality is attributed 
to a lowering of many risk factors in the population (Figure 5).36 Similar results have 
been obtained in other countries (Figure 6).36
Figure 4. Coronary Heart Disease mortality trends in Beijing 1984 to 1999: additional deaths 
attributable to risk factor changes and deaths prevented or postponed by treatments. 
(By permission from Critchley et al 35).
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Figure 6. Percentage of the decrease in deaths from coronary heart disease attributed to treatments 
and risk-factor changes in some populations. In the New Zealand study, 1974 to 1981, the analysis 
focused on specific treatments and inferred contribution from risk factors. In the Finnish study, 1972 
to 1992, the analysis focused on risk factors and inferred contribution from treatments. 
(By permission from Ford et al36).
Figure 5. Coronary Heart Disease mortality trends in United States of America 1980-2000.
(By permission from Professor L Rydén, who adopted it from Ford et al 36). 
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Risk factors for diabetesThe American Nurses’ Health Study recruited almost 85 000 female nurses free from 
cardiovascular disease and diabetes and followed them for 16 years.37 Individuals with 
the following five lifestyle traits - normal weight, a healthy diet rich in cereal fibre and polyunsaturated fat, regular physical activity, moderate alcohol consumption and no 
smoking - had a 90% lower incidence in diabetes than those without these traits.37 Notably these factors were similar to those brought forward by the INTERHEART 
study for acute myocardial infarction.32, 37 Even if several risk factors interact, obesity is considered the strongest for the development of diabetes and is believed to explain 
more than 80% of all cases.19, 37 A similar risk pattern for diabetes has been observed in 
European and Asian populations.19 In USA overweight and obesity have increased rapidly the past three decades, presently affecting 70% of the adult population, thereby inducing a dramatic change of the 
risk factor pattern.38 As can be expected, there has been an parallel increase in the 
prevalence of diabetes. Between the age of 20-79 there is currently 24 million people 
diagnosed with diabetes comprising around 9% of the adult American population.16 Today the lifetime chance to develop diabetes in USA is 30-40% posing a great threat to 
public health.38 Sadly the obesity epidemic has caused an increase of childhood diabetes 
leading to complications e.g. kidney failure in early ages.39 All together obesity and its associated diseases, such as diabetes and cardiovascular disease, constitute such a big 
threat to public health that life expectancy is expected to decrease for the first time in 
centuries in USA if the epidemic is not stopped.2, 40 In this respect recent reports that 
obesity has started to level out are encouraging for USA and Europe.41 Unfortunately, reports indicate that there is a rapid increase of obesity in Asia and Africa bringing 
diabetes in its wake, calling for preventive initiatives.35, 42, 43 
Changes in the risk profile of a population
As illustrated, the risk profile of a population can change rapidly over time when new 
trends in lifestyle become popular.44 This is both encouraging and worrisome since it gives hope to preventive efforts, but should serve as an admonition for the changes 
caused by the increasingly common sedentary lifestyle. Given the slow adaptation of the human genome over thousands of years, genetic factors will have a miniscule impact on the prevalence of cardiovascular disease and diabetes compared to the fast changes 
in the lifestyle of a society.45 This underlines the importance of keeping up to date with 
epidemiological changes and their reasons when working with prevention.32 45, 46 
Regional differencesAs has been empasised the risk factors for cardiovascular disease and diabetes are similar and seemingly universal19, 32. This does not contradict regional difference in disease 
burden.21, 33 Although these conditions are more common in high income countries the 
age standardised mortality is higher in low and middle income countries.21 The countries with the most pronounced burden are those experiencing a ‘double burden’ of disease, 
i.e. still not free from communicable diseases and malnutrition but at the same time suffering an increasing morbidity and mortality related to non-communicable diseases, 
due to the adoption of a western lifestyle.31 It is unfortunate that the healthcare systems 
in these countries often are incapable of coping with the ‘new’ diseases.21 Different 
Viveca Gyberg
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populations and regions of the world have to focus on their specific challenges. On a positive note countries starting their epidemiological transition towards predominance of non-communicable disease later than others often move faster than those originally 
challenged.31 A summary of the disease burden and life expectancy of the world’s 
regions is summarized in Figure 7.
European health challengesIn Europe cardiovascular disease kills four million people each year which represents 50% of the regional mortality33 putting it in focus for attempts to improve the health 
in this region.31 The estimated prevalence of diabetes is 8.5%, affecting 56 million 
individuals across Europe, ranging from 15% in Turkey to 2% in Azerbaijan.16 It is important to remember that even in Europe, a region which is well-off compared 
to others, there is a large variation between countries.33 Despite a recent decline33, populations from Eastern Europe have a higher mortality in cardiovascular disease 
than those living in the Northern and Western parts.31, 33 This east-western gradient is explained by a multitude of factors including smoking habits, a diet high in saturated fat and low in fruit and vegetables and low physical activity, factors that at least partly 
relate to the socioeconomic climate.47 
Figure 7. Percentage distribution of deaths by group of causes in 2008 and life expectancy at birth 
2005-2010 for the world and in selected regions Group I includes: communicable diseases as well 
as maternal, perinatal and nutritional conditions, Group II: non-communicable diseases, Group III: 
death resulting from intentional and unintentional injuries. 
(From: Changing Levels and Trends in Mortality: the role of patterns of death by cause (United Nations publica-
tion, ST/ESA/SER.A/318). United Nations, Department of Economic and Social Affairs, Population Division, © 
2012 United Nations. Reprinted with the permission of the United Nations).
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Prevention
Definitions In medicine, prevention refers to all actions taken to prevent disease or disability at both 
the individual, group and societal levels.48 The main objective of prevention is to reduce 
morbidity, improve quality of life and increase longevity.18 The argument to encourage prevention is simply the assumption that ‘it is better to be healthy than ill or dead’.46 Preventive efforts can be instituted through all stages in life but is commonly divided into three levels more or less linked to each other:48
Primordial prevention is the prevention of the development of risk factors in healthy 
individuals and involves gaining healthy habits from birth throughout life.
Primary prevention comprises interventions designed to modify adverse levels of risk 
factors once present. Examples are smoking cessation, stimulating consumption of 
healthy food products and encouraging physical activity.
Secondary prevention comprises interventions designed to treat an already established 
disease to limit recurrent events and premature mortality. Examples are lipid lowering 
treatment and rehabilitation programs after a myocardial infarction. 
Theoretical aspectsPrevention may be directed towards high-risk individuals or to entire populations, a 
distinction that is applied worldwide in preventive initiatives, guidelines and reports.18, 21, 46, 49-51 High-risk and population approaches are illustrated in Figure 8. The high-risk prevention targets subgroups of people, who have a higher than average risk to 
develop a disease, such as smokers, the obese or post myocardial infarction patients.46 
It has been claimed that this is the most efficient form of prevention since it targets 
those who need help the most.18 Furthermore the humanitarian aspect, that we have an 
Figure 8. Population and high-risk strategy for prevention. (By permission from Professor L Rydén)
Viveca Gyberg
20
obligation to take care of individuals who are unhealthy since it could happen to anyone 
of us, has been brought forward.46 A high-risk approach will improve morbidity and often mortality of these individuals but has a limited potential to change the population based morbidity and mortality pattern due to the relatively limited number of people 
addressed. In contrast the population approach targets risk factors in an entire population 
regardless of individual risk profiles.46 A pioneer in the field of prevention was Geoffrey Rose who emphasised that the high-risk individuals of a society are always 
dependent on the mean characteristics of a society in general.46 This opinion is based on the assumption that an individual cannot be separated from the environment, social 
structures and culture in which they live.45, 48, 52 Rose argues that even a modest lowering 
of a risk factor on the population level, e.g. a few mm Hg of blood pressure, will be followed by a substantial decrease in future illness due to the high number of people 
that will slightly decrease their risk factor level.46 This theory gains further support by changes seen in the prevalence of cardiovascular disease and diabetes in USA22,36,37 and China35 as presented in Figure 4 and 5. Rose argued that preventive initiatives on a population level should always include both a population-wide approach, in order to target the environmental causes of illness, and a high-risk approach to help those in 
greatest need.46
Population-based prevention As already emphasised, interventions aiming at the general population are considered to have the largest potential to make a major impact on the prevalence of non-
communicable diseases.21 Since atherosclerosis starts as early as during the teenage 
years primordial prevention should play an important role in preventing such disease.48 Regarding cardiovascular disease and diabetes the evidence supporting primordial 
prevention is less conclusive than for primary- and secondary preventive initiatives.48 
The reason for this is that it is difficult from a methodological point of view to design 
trials in a large population. The selection of a control group is for example difficult considering the long follow-up period needed and the demands to completely avoid 
potential confounding factors. Interventions aiming at risk factor reduction such as lowering salt consumption and eliminating tobacco use as well as promoting a healthy diet and physical activity are, however, measures believed to prevent future 
disease in a population.48 This kind of strategy often requires changing the cultural, 
social and physical environment to encourage healthy behaviour.48 For a population approach to work, different stakeholders, among them politicians, corporations and 
non-governmental organisations, need to work together towards a common target.48, 53 A study investigating British middle-aged men estimated that mortality from cardiovascular disease may be reduced by 45% by reducing their average blood pressure 
and cholesterol levels by 10%.51 As a comparison treating individuals at 30% risk of acquiring cardiovascular disease in the upcoming ten years (6% of the population) with a combination of statins, ß-blockers, ACE-inhibitors and aspirin would reduce 
mortality by 11% in the studied population.51 It would have been possible to increase the mortality reduction to 34% if the 10-year risk threshold was set at 20% or to a 49% 
reduction if the threshold was reduced to 15%. At these latter risk levels, 25% and 50% respectively of the population without any symptoms of cardiovascular disease would 
be put on a range of cardioprotective drugs.51 
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A successful example of prevention by means of legislation at a population level are the presently widely spread smoking bans, limiting one of the strongest risk factors 
of cardiovascular disease. A systematic review and a meta-analysis showed that AMI declined about 17%, with the greatest effect in younger age groups and non smokers, 
adding further proof to the large impact of wide-spread health policies.54 
The North Karelia Project 
The Finnish North Karelia Project initiated in 1972 is the first example of the strength of 
a community-based prevention project.53 It was launched in response to a local petition asking for urgent and effective help to reduce the world leading cardiovascular disease 
mortality in this area. The project was executed through cooperation by the health care services, schools, non-governmental organisations, media campaigns, supermarkets, food industry and politicians with the shared goal to reduce risk factors for cardiovascular disease by changing the lifestyle of the population. A comprehensive evaluation of the results was part of the initiative, which soon became an important model for national 
and international preventive programs. The North Karelia Project revealed that a major decline in cardiovascular disease mortality, indeed of an extent predicted before the project started, could be obtained by decreasing cardiovascular risk factors essentially 
by non-pharmacological tools as presented in Figure 9. During the project period age-adjusted mortality in coronary artery disease declined more in North Karelia than anywhere else in Finland amounting to a reduction in mortality from coronary heart 
disease by 80% in men and 83% in women until 2006.53 Indeed life expectancy at the time of birth increased from 64 to 75 years in men and from 72 to 81 years in women 
thereby approaching the national average in Finland.53, 55  
Figure 9. Decline in risk factors (smoking, blood pressure and cholesterol) and mortality in the North 
Karelia Project. 
(By permission from Varitainen et al55)
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Prevention of high-risk individualsPrimary and secondary preventive programmes for patients with cardiovascular disease and diabetes usually includes smoking cessation, healthy food choices, regular physical 
activity and control of hypertension, hyperlipidaemia and dysglycaemia.17, 49 A target-driven multifactorial treatment has the potential to improve the future prognosis in 
patients.17, 30, 49 Interventions in individuals with risk factors present for diabetes have been shown to reduce the relative risk to develop diabetes between 28-67% and also to 
improve the cardiovascular risk profile.17, 56-61 The Finnish Diabetes Prevention Program 
randomized middle-aged men and women with IGT to a four years long prevention 
program aiming at a modest weight reduction (5%), some dietary modifications and increased physical activity (4h per week or more) and were able to show a sustained 
diabetes risk reduction for thirteen years despite cessation of the program.59 In 1986 the prospective and randomised Da Qing Diabetes Prevention Study people with impaired glucose tolerance (n=439) were subjected to a six years long intervention 
program aiming at exercise and diet. When they were compared to persons serving as a control group (n=138) after 23 years of follow-up there was a reduction in the incidence of 
diabetes, (Hazard Ratio 0.45) and a lower cardiovascular (Hazard Ratio 0.71) and all-cause 
mortality (Hazard Ratio 0.59) in the intervention group.20 The mechanism responsible for the decreased risk was believed to be the delayed onset of diabetes achieved by the 
program.20 This highlights that the process leading to cardiovascular disease takes decades 
but that this process can be changed by a lifestyle intervention program.While both primary and secondary prevention is based on non-pharmacological tools, secondary prevention always, and primary prevention sometimes, involves pharmacological treatment by drugs such as aspirin, β -blockers, Angiotensin-Converting 
Enzyme inhibitors/Angiotensin Receptor Blockers, statins and glucose-lowering drugs. A summary of the relative risk reduction achieved by different preventive interventions 
after myocardial infarction is presented in Table 2. In patients with the combination of diabetes and coronary artery disease the prognosis can be improved to a level almost equivalent to that in patients without diabetes by means of a comprehensive 
pharmacologic treatment.62, 63 Given their higher absolute risk, the number needed to treat to avoid one cardiovascular event is substantially lower in patients with than in 
those without diabetes.62 
Table 2. Relative lowering of mortality by institution of preventive interventions in patients with 
established coronary artery disease. 
Intervention Lowers mortality 
by (RR)
Reference
Smoking cessation + healthy diet + exercise* 54% Chow et al. Circulation 201064
Smoking cessation 36% Critchley et al. JAMA 200365
Statin 31% Wei et al. BMJ 200566
Stress management** 28% Gulliksen et al. Arch Intern Med. 201167
ACE/ARB 27% Hennekens et al NEJM 199668
Exercise 26% Taylor et al. Am J Med 200469
β-blockers 23% Freemantle et al. BMJ 199970
Aspirin 15% Collaborative meta-analysis. BMJ 200271
* Adherence to smoking abstinence, dietary advice and exercise advice.
** Non-significant lowering of mortality but a significant lowering of a recurrent myocardial infarction by 48%.
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Development and implementation of practice guidelinesUpon the initiative of the European Society of Cardiology (ESC) and in collaboration with other groups of European health care professionals, among them the European Atherosclerotic Society, the European Hypertension Society, The European Heart 
Net Work and the European Association for the Study of Diabetes, the first issue of evidence based guidelines for cardiovascular disease prevention in clinical practice was 
published in 1994. These guidelines have been updated regularly with the most recent 
version published in 2013.17, 49 In parallel, and under the auspices of the European Society of Cardiology, the EUROASPIRE (EUROpean Action on Secondary and Primary prevention of coronary heart disease In order to Reduce Events) surveys were initiated 
to study the practice of prevention across Europe. Despite some improvement over time, EUROASPIRE I, II, III demonstrated a surprisingly high prevalence of unhealthy lifestyles, an inadequate use of drug therapies and an inability to achieve guideline recommended treatment targets for blood pressure and lipid control in patients 
with established cardiovascular disease and in people at high risk of such disease.72 
Moreover there was a wide practice variation between countries.73 This ESC initiative has been supplemented by educational efforts and the release of supporting products 
e.g. pocket guidelines, educational kits, web-based questions with links to the guidelines 
and translations of the guidelines to most European languages. The intention is to work towards an improved patient management by bringing new knowledge and gain 
experience together and to evaluate the outcome as illustrated in Figure 10.
Figure 10. Research, implementation and surveys evaluating real world practice all contribute 
development of new guidelines. (By permission from Professor L Rydén)
Education
Guidelines
Surveys
Research
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Screening for people at risk
Screening for diabetes in a general population 
A main concern is that many people with diabetes or its pre-states are unrecognized. The International Federation for Diabetes made a global estimate that as many as 175 
million people with diabetes are unaware of their condition. In addition 316 million 
(6.9% of the adult population) are believed to have IGT.16, 74 This means that there is an 
emerging need to identify these people, who may benefit from preventive initiatives if discovered, and several risk scores have been developed to help identify individuals 
with elevated risk for diabetes as well as coronary artery disease.75-78 The Finnish Diabetes Risk Score (FINDRISC) was created as a feasible way of identifying 
people at risk for diabetes the upcoming 10 years (Figure 11). According to a review of 145 risk scores, seven were brought forward as feasible in clinical or public health 
practice and FINDRISC was one of them.78 A validation review from 2014 confirmed 
the discriminatory power of the FINDRISC-questionnaire in a European setting.79 It is based on eight simple questions concerning age, BMI, waist circumference, intake of fruit and vegetables, physical activity, high blood pressure, history of high glucose value and family history of diabetes that in combination provides an accurate assessment 
of the risk of developing diabetes the upcoming ten years. FINDRISC also provides a 
good prediction of the risk to develop cardiovascular disease.80 The risk score (points: 
0-26) allocates the responding person to one of five risk groups with a sensitivity 
(that a person developing diabetes is identified as such) of 78%, a specificity (that a 
person not developing diabetes is identified as such) of 77% and a predictive value of a 
negative test of 99%.77, 80 The FINDRISC, which was developed in a Finnish population, has been tested and found accurate in identifying individuals at risk for diabetes and/or 
cardiovascular disease not only in Finland but in several other countries e.g. Germany, Sweden, Spain, Greece, Iran, Turkey, the Philippines, Hungary, Mexico, Italy, Norway and 
the Netherlands.77, 81-92 The simplicity of the questionnaire makes it possible to screen 
individuals and to initiate primary prevention in those presenting with high risk. The test in it self also provides information on important factors and thus serves as an 
intervention. It does also provide a potential of early diagnosis since those presenting 
with high risk are recommended a laboratory-based evaluation of their glycaemic state.
Screening for dysglycaemia in patients with coronary artery diseaseConsidering the serious prognostic implication of dysglycaemia in the presence of 
coronary artery disease it is of great importance to identify such patients. Still attempts to 
diagnose dysglycaemia are often neglected.24 In asymptomatic patients three diagnostic tests are recommended, FPG, 2hPG and HbA1c, to identify dysglycaemia as presented in 
Table 1.10, 17, 93 Current guidelines endorse the use of all three.10, 14, 17, 93, 94 There is, however, 
an ongoing debate on which test is to be preferred. In brief, the objections to the OGTT are mainly focusing on the time (2 hours) needed to perform the test and its presumed 
lack of reproducibility. A low sensitivity to detect diabetes and a, compared to the 2hPG, limited ability to predict future cardiovascular events are objections to the use of FPG 
and HbA1c only.95, 96 Lately the interest in replacing the OGTT, as recommended by European guidelines on the management of diabetes, prediabetes and cardiovascular disease17, with HbA1c alone or in combination with FPG has increased.97, 98
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Figure 11. The Finnish Diabetes Risk Score, continuing on next page.
(By permission from Professor J Tuomilehto).
TYPE 2 DIABETES RISK ASSESSMENT FORM
Circle the right alternative and add up your points.
1. Age
0 p.  Under 45 years
2 p.  45–54 years
3 p.  55–64 years
4 p.  Over 64 years
2. Body-mass index
(See reverse of form)
0 p.  Lower than 25 kg/m2
1 p.  25–30 kg/m2
3 p.  Higher than 30 kg/m2
3. Waist circumference measured below the ribs 
(usually at the level of the navel)
    MEN        WOMEN
0 p. Less than 94 cm Less than 80 cm
3 p. 94–102 cm 80–88 cm
4 p. More than 102 cm More than 88 cm
4. Do you usually have daily at least 30 minutes 
of physical activity at work and/or during leisure 
time (including normal daily activity)?
0 p.  Yes
2 p.  No
5. How often do you eat vegetables, fruit or 
berries?
0 p.  Every day
1 p.  Not every day
6. Have you ever taken medication for high 
blood pressure on regular basis?
0 p.  No
2 p.  Yes
7. Have you ever been found to have high blood 
glucose (eg in a health examination, during an 
illness, during pregnancy)?
0 p.  No
5 p.  Yes
8. Have any of the members of your immediate 
family or other relatives been diagnosed with 
diabetes (type 1 or type 2)?
0 p.  No
3 p.  Yes: grandparent, aunt, uncle or first   
  cousin (but no own parent, brother, sister   
  or child)
5 p.  Yes: parent, brother, sister or own child
Total Risk Score
  The risk of developing    
  type 2 diabetes within 10 years is
Lower than 7 Low: estimated 1 in 100    
   will develop disease
7–11  Slightly elevated:
   estimated 1 in 25    
   will develop disease
12–14  Moderate: estimated 1 in 6    
   will develop disease
15–20  High: estimated 1 in 3   
   will develop disease
Higher   Very high:   
than 20  estimated 1 in 2 
   will develop disease
Test designed by Professor Jaakko Tuomilehto, Department of Public Health, University of Helsinki, and Jaana Lindström, MFS, National Public Health Institute. 
Please turn over 
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WHAT CAN YOU DO 
TO LOWER YOUR RISK OF DEVELOPING TYPE 2 DIABETES?
You can’t do anything about your age or your genetic 
predisposition. On the other hand, the rest of the fac-
tors predisposing to diabetes, such as overweightness, 
abdominal obesity, sedentary lifestyle, eating habits 
and smoking, are up to you. Your lifestyle choices can 
completely prevent type 2 diabetes or at least delay its 
onset until a much greater age.
If there is diabetes in your family, you should be care-
ful not to put on weight over the years. Growth of the 
waistline, in particular, increases the risk of diabetes, 
whereas regular moderate physical activity will lower the 
risk. You should also pay attention to your diet: take care 
to eat plenty of fibre-rich cereal products and vegetables 
every day. Omit excess hard fats from your diet and fa-
vour soft vegetable fats.
Early stages of type 2 diabetes seldom cause any 
symptoms. If you scored 12–14 points in the Risk Test, 
you would be well advised to seriously consider your 
physical activity and eating habits and pay attention 
to your weight, to prevent yourself from developing 
diabetes. Please contact a public-health nurse or your 
own doctor for further guidance and tests.
If you scored 15 points or more in the Risk Test, you 
should have your blood glucose measured (both fast-
ing value and value after a dose of glucose or a meal) 
to determine if you have diabetes without symptoms.
BODY-MASS INDEX
If your body-mass index is 25–30, you will benefit 
from losing weight; at least you should take care 
that your weight doesn’t increase beyond this. If 
your body-mass index is higher than 30, the adverse 
health effects of obesity will start to show, and it 
will be essential to lose weight.
BODY-MASS INDEX CHART
The body-mass index is used to assess whether a 
person is normal weight or not. The index is calculated 
by dividing body weight (kg) by the square of body 
height (m). For example, if your height is 165 cm and 
your weight 70 kg, your body-mass index will be 
70/(1.65 x 1.65), or 25.7.
normal weight                          mild obesity                              marked obesity       severe obesity           morbid obesity
Height (cm)
Weight (kg)
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For instance the National Institute for Health and Care Excellence guideline from the United Kingdom discourages from the use of an OGTT in patients with acute coronary 
syndromes with normal FPG and HbA1c.98 The ADA recently emphasised the lack of concordance between the different diagnostic methods and concluded that “Further research is needed to better characterise patients whose glycaemic status might be 
categorized differently by two different tests (e.g. FPG and HbA1c) obtained in close 
temporal approximation”.93
Ethical considerations of estimating risk
The preventive paradox and the risk of risk awareness Preventive measures applied on a population level may force people to change 
behaviour in order to decrease morbidity in a few.46 This is what Geoffrey Rose calls the preventive paradox: ‘a preventive measure that brings large benefits to the community 
offers little to each participating individual’.46 Furthermore, even if the estimation of 
risk is based on the best available data it is not the equivalent to the truth.44, 99 This 
means that the risk may be both over- and underestimated. Obtained information on 
high risk may cause anxiety and stress in an individual - sometimes a disease in itself.99 On the other hand, if the risk is erroneously estimated as low, an individual might take comfort in the already existing lifestyle not being able to prevent a potential deadly 
condition. The risk of a population might also be misclassified since the behaviour of a 
society changes over time making a once valid test inaccurate. This has been seen for SCORE, a risk score estimating cardiovascular risk, in Russia in the beginning of 2014 
where the risk to develop cardiovascular disease was underestimated.100 To translate epidemiological data derived from populations to individual risk is not uncomplicated and the estimation of risk always has to be cautiously interpreted in the light of societal 
trends and individual factors.44, 99 In 1968 Wilson at the Ministry of Health in the United Kingdom and Jungner at the Sahlgrenska Hospital in Gothenburg, Sweden listed criteria 
that should be fulfilled before a screening program can be accepted as justified.101 These 
criteria were revisited and further developed in 2008 by Andermann et al.101 presented 
in Table 3. These criteria should always be considered before a screening program is 
initiated. 
Policymakers’ actions to battle cardiovascular disease and diabetesThe increase of cardiovascular disease, diabetes and other non-communicable diseases, in combination with available evidence that prevention is possible54-71, 102 has caused the 
international community to act.21, 31,  103-104 An important step was taken by the European Heart Network which together with the European Society of Cardiology on February 14, 2000 introduced the St Valentine’s declaration that: ‘Every child born in the new 
millennium has the right to live until the age of at least 65 without suffering from avoidable 
cardiovascular disease’.105 In 2002 the European Society of Cardiology launched ‘a 
common strategy for member states to reduce cardiovascular deaths by 40%’.105 These initiatives led to an increased collaboration between health care professionals and politicians and the European Heart Health Charter (EHHC) was launched in June 2007 at the European Parliament in Brussels as a joint project by European Society of 
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Cardiology, European Heart Network with the support of the European Commission and the WHO region Europe.105 The charter was summarised in a European phone 
number to health: 03514090530 as explained in Table 4.In 2011 United Nations (UN) organised two high level meetings regarding health: 
the first concerned AIDS and the second non-communicable diseases, not the least 
cardiovascular disease and diabetes.52  This meeting resulted in the Political Declaration on the Prevention and Control of Non-Communicable Diseases listing prevention as the 
most important action to control the threatening global flare of non-communicable 
diseases.52 At the 65th World Health Assembly in May 2012 the 194 WHO member states adopted as a global target to reduce premature mortality from non-communicable diseases by 25% by 2025, 
also known as 25 by 25.106 Important areas that needed to be addressed to achieve this goal were listed: improved lifestyle (decrease harmful alcohol use, decrease tobacco use, lower sodium intake, increased physical activity), control of risk factors (blood pressure, 
Table 3. The Wilson and Jungner screening criteria developed by Andermann et al.101
1.  The condition sought should be an important health problem
2.  There should be an accepted treatment for patients with recognized disease
3.  Facilities for diagnosis and treatment should be available
4.  There should be a recognizable latent or early symptomatic stage
5.  There should be a suitable test or examination
6.  The test should be acceptable to the population
7.  The natural history of the condition, including development from latent to declared disease,  
should be adequately understood
8.  There should be an agreed policy on whom to treat as patients
9.  The cost of case-finding (including diagnosis and treatment of patients diagnosed) should be 
economically balanced in relation to possible expenditure on medical care as a whole
10. Case-finding should be a continuing process and not a “once and for all” project.
Synthesis of emerging screening criteria proposed over the past 40 years
• The screening programme should respond to a recognized need
• The objectives of screening should be defined at the outset
• There should be a defined target population 
• There should be scientific evidence of screening programme effectiveness
• The programme should integrate education, testing, clinical services and programme management
 • There should be quality assurance, with mechanisms to minimize potential risks of screening  
• The programme should ensure informed choice, confidentiality and respect for autonomy 
• The programme should promote equity and access to screening for the entire target population 
• Programme evaluation should be planned from the outset  
• The overall benefits of screening should outweigh the harm
Table 4. Healthy targets as set in the European 
Heart Health Charter.
0 No use of tobacco,
3 Three km of daily walking
5 Five daily servings of fruit and vegetables
≤140/90 In blood pressure
<5 mmol/l in total cholesterol
<3 mmol/l in LDL-cholesterol
0 No diabetes
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obesity and diabetes) and better treatment (eligible individuals to be treated with adequate pharmacologic agents to prevent cardiovascular disease and drugs and new 
technologies to be made accessible to as many as possible).106 Still many policymakers 
do not prioritise prevention of non-communicable disease.21 The obstacles are complex, 
including difficulties in implementing research in clinical practice and a multitude 
of other factors involving social, economic, industrial and cultural forces. Relatively few studies have investigated the processes related to preventive interventions on a 
population level, processes that deserve to be further explored.108-111One of the initiators of the North Karelia Project, the former director for the Department for non-communicable diseases at the WHO and Past President of the World Heart Federation Pekka Puska stated that: 
‘Although much will certainly still be learnt in the future, very much is thus known 
already to serve prevention. Actually so much is known that the main question for [non-
communicable disease] prevention is not “what should be done”, but “how it should be 
done”. The key question is: how can existing knowledge best be applied for effective 
prevention in real life’.112 
Viveca Gyberg
30
AIMS
The overall aim of this thesis is to advance the understanding of different levels of prevention: primordial-, primary- and secondary prevention using both a population and a high-risk based approaches in patients with cardiovascular disease and/or 
diabetes.
Specific aims are
1. To investigate the perception of key policymakers on cardiovascular disease in Europe and what actions and obstacles they see to improve health on a 
population level. (Study I)
2. To investigate if FINDRISC as an online questionnaire, is a feasible way to identify high-risk individuals as well as risk typing the population of an 
organisation. (Study II)
3. To investigate if patients with coronary artery disease, with and without diabetes, are managed according to recommendations given in European 
Practice Guidelines. (Study III and IV)
4. To determine which screening test has the best capacity to detect dysglycaemia 
in patients with coronary artery disease. (Study V)
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MATERIAL AND METHODS
Summary
This thesis used data from four different cohorts summarised in Table 5.
Table 5.  An overview of the studies that comprises the fundament for the thesis.
Study I II III IV-V
Study/Data source Gyberg-Rydén Policy-
maker questionnaire
Webb-QPS EUROASPIRE III EUROASPIRE IV
Time of data 
collection
2008 2007 2006-2007 2012-2013
Source population Policymakers in 32 
European countries
Employees at 
the Karolinska 
University 
Hospital, 
Stockholm, 
Sweden
Patients with 
established 
coronary artery 
disease aged 18-
80 in 22 European 
countries
Patients with established 
coronary artery disease 
aged 18-80 in Europe in 24 
European countries
Design Descriptive Descriptive Cross-sectional 
survey
Cross-sectional survey         
Study population Responders to the 
Gyberg-Rydén policy-
maker questionnaire
Responders to 
the FINDRISC-
questions in 
Webb-QPS
All patients with 
an established 
glucometabolic 
status
IV: All individuals with an 
established glucometabolic 
status 
V: All individuals without 
diabetes in whom FPG, 
2hPG and HbA1c were 
available
Number in study 
population
116 3029 6588 IV: 6187
V: 4004
Outcomes (1) Awareness and 
perceived proximity to 
the EHHC-targets 
(2) Perceived obstacles 
to cardiovascular health
(3) Actions deemed 
important to improve 
cardiovascular health 
(4) What measures 
are used to promote 
cardiovascular health
(1) Response rate 
(2) Identification 
of a population 
that could 
benefit from 
preventive 
interventions
(1) Use of 
pharmacologic 
treatment.
(2) Fulfilment of 
risk factor targets 
set in the European 
prevention 
guidelines
IV: (1) Use of 
pharmacologic treatment.
(2) Fulfilment of risk 
factor targets in European 
prevention guidelines
V: Number of individuals 
identified with 
dysglycaemia by FPG, 2hPG 
and HbA1c 
Adjustments None None Age, gender, 
clustering within 
centres
IV: Age, gender, BMI, waist 
circumference, clustering 
within centres
V: Age and gender
Statistical analyses Descriptive Descriptive Patient 
characteristics 
across groups: Chi-
square. Analysis 
of risk factors: 
multilevel logistic 
modelling
IV: Patient characteristics 
across groups: Chi-square. 
Analysis of risk factors: 
multilevel logistic modelling    
V: Patient characteristics 
included/excluded: Fisher’s 
exact test and the Mann-
Whitney U test. Exclusive 
glycaemic groups: Logistic 
regression 
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Study I
AimTo investigate the perception of key policymakers on cardiovascular disease in Europe 
and what actions and obstacles they see to improved health on a population level.
DesignA descriptive study among policymakers was performed using a by the authors created questionnaire
Study PopulationA total of 116 leading representatives of four professional structures in 32 European 
countries were identified. Two of the professional structures were governmental: Ministries of Health (health politicians) and public health institutes (public health 
officials), and two were non-governmental: national cardiac societies (health 
professionals) and national heart foundations (public representatives). In each of 
these organisations the executive officer was addressed with the intention to assess 
the perception of individual, key policymakers. The responders were divided into the 
four defined professional categories and four European regions (north, south, east, 
west) as presented in Table 9 found in the results section.
The pilot investigation and development of the questionnaireDuring the spring of 2007 a pilot questionnaire was distributed to representatives from the Ministries of Health, the Public Health Institutes and National Cardiac 
Societies in four countries: Sweden, Croatia, United Kingdom and Portugal. The pilot study tested a set of questions that had been produced with the aim to get an opinion 
on how different policymakers experienced the EHHC. The respondents were asked not only to reply to the questionnaire but also to express their opinion on individual 
questions in text. The conclusion was that, following modifications, the questionnaire 
had the prerequisite to provide the requested information. It was adapted into its 
final form and in 2008 e-mailed to all recipients together with a copy of the EHHC and 
an introductory letter. 
The identified policymakers were asked to address four issues: (1) previous knowledge and perceived proximity to the EHHC-targets, (2) perceived obstacles to cardiovascular health, (3) actions deemed important to improve the cardiovascular 
situation, and (4) what measures are applied to promote cardiovascular health. 
Previous knowledge of the EHHC was responded to as either ‘yes’ or ‘no’. Obstacles to and actions towards improving cardiovascular health were graded by identifying the, for the respondent, three most important factors out of eight listed possibilities (Table 
6). National attainment of the targets set out in the EHHC (Table 4) was rated from 1 
(far from goal) to 10 (on target). Two examples of the questions are presented below. These results were compared to European statistics on cardiovascular disease from 
the Euro Heart Survey.113 The use of predefined measures to improve cardiovascular 
health, as presented in Table 7, were rated from 1 (not at all) to 10 (full extent). 
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                          Far from goal                                                      Close to goal         On target
   1 2 3 4 5 6 7 8 9 10 No opinion
Male
Female
Children <18 years
Examples of two questions in the questionnaire:
In your experience/opinion, which are the three most important actions or 
measures to be taken at a national level in order to improve cardiovascular health? 
Number your answer 1 to 3 in order of importance.
Political Economical Organisational Media related
Increase awareness Change attitudes Lifestyle oriented Other
 
Comments:_____________________________________________
The EHHC lists eight characteristics associated with cardiovascular health. If 
these characteristics were national goals, how far or how close to them is the 
population in your country at present?
No use of tobacco (all targets in Table 4 were assessed similarly)
Table 6. Factors affecting obstacles to, and future actions needed to, improve cardiovascular health.
Political: Factors originating from individuals, groups or organisations connected to a government 
or multigovernmental organisation, such as your own government, the EU or the UN
Economical: Lack of adequate financial recourses to achieve wanted goals
Organisational: Lack of coordination of active organisations, lack of an organisation handling 
cardiovascular prevention, etc
Media/Media related: No consistent systematic promotion/debate/information on cardiovascular 
prevention in TV/Newspapers/Radio/etc
Awareness/Increase awareness: Lack of sufficient knowledge of why and how to prevent 
cardiovascular disease within the population
Attitudes/Change attitudes: Refers to that knowledge of why and how to prevent cardiovascular 
disease exists within the population but there is no will to do anything about it
Life style/Life style oriented: Refers to too expensive and/or low availability of healthy options such 
as cheap vegetables, sport facilities, sport classes in schools, tobacco control measures, etc
Other: None of the above
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Statistical analysis
The information provided was analysed using Microsoft Excel. No statistical analysis 
was undertaken. Descriptive analysis was judged to be more suitable given the limited 
number of participants and the answers dependency on one individual key policymaker.
Ethical considerations
No specific ethical issues were identified and it was up to the discretion of the person 
asked to respond to the questionnaire. The results were grouped and presented 
anonymously whenever possible. 
Study II
AimTo investigate if FINDRISC as an online questionnaire is a feasible way to identify high-
risk individuals as well as risk typing an organisation.  
Design
A descriptive analysis was undertaken using answers obtained from a questionnaire. 
Study populationThe study population was 5166 employees in 2007 at the Karolinska University Hospital 
in Stockholm, Sweden. They all received a link to an online questionnaire, called the 
Webb-QPS, specifically sent out to explore leadership and health in an e-mail inviting 
them to respond. FINDRISC was incorporated in this questionnaire. In the present 
analysis study participants who answered the FINDRISC-questionnaire were included. 
All study participants with self-reported diabetes were excluded.
Table 7. Measures as part of public national attempts to improve cardiovascular health
1 Tobacco tax
2 Legislation prohibiting smoking in public areas
3 Alcohol tax
4 Prevalence of national information campaigns promoting cardiovascular health initiated by 
governmental organisations
5 Prevalence of national information campaigns promoting cardiovascular health initiated by non-
governmental organisations
6 Integration of relevant content into national school educational systems
7 Medical professionals identifying high-risk individuals in the healthcare system
8 Advocacy for healthy lifestyles by medical professionals
9 Subsidising physical activities through tax/other incentives at a corporate level
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The questionnaireThe questionnaire assessed the psychosocial environment and major health issues as 
follows: 1. Back- and neck pain; 2. Mental disease; 3. Diabetes; 4. Chronic obstructive 
lung disease; 5. Cardiovascular disease.114 It was adaptive, which means that the number of questions to be answered related to the response to the main question 
on a specific subject, i.e. a person with more problems received several questions. A 
slightly modified version of the eight FINDRISC-questions was incorporated into the questionnaire in order to adapt the questions to the technical structure of the Webb-
QPS. Questions 1, 2, 3, 5, 7 and 8 were identical to the original FINDRISC (Figure 11). 
Question 4 had four options on physical activity instead of 2. Question 6 asked “if you 
currently are on any blood pressure lowering drugs” instead of “if you ever had taken 
such drugs”. The amendments were approved by the creator of FINDRISC (J Tuomilehto: 
Personal communication). The FINDRISC-questions were scattered throughout the 
questionnaire. In order to measure waist circumference (Question 3), a tape measure was sent to all recipients of the questionnaire while it was assumed that tools to 
measure weight and height to calculate BMI (Question 2) would be easily available. Five 
reminders were sent out before study closure. 
Statistical Analysis
The information provided was analysed using SPSS. No statistical analysis were 
undertaken since a descriptive analysis was judged to be sufficient. The study 
participants were divided into the FINDRISC-risk groups as presented in Figure 11.
Ethical consideration The study was approved by the Regional Ethics Committee in Stockholm, Sweden DNR: 
2006/844-31. Participation was voluntary and anonymous. All participants signed an 
informed consent. All were informed that the questionnaire would assess their work satisfaction and that feedback to managers was reported at a group level only if there 
was a minimum of 10 responders and 50% response rate in the group.
Study III
AimTo investigate if patients with coronary artery disease with and without diabetes are managed according to recommendations given in European Practice Guidelines as 
presented in Table 8.
Design
Study III is based on data from the study EUROASPIRE IV, an observational, cross sectional survey conducted at 76 centres in 22 European countries between 2006-
2007, interviewing and investigating patients with established coronary artery disease. A total of 13 935 medical records were scrutinised in the search for study participants 
and 8966 (64%) attended the interview. 6558 (73%) patients in whom the glycaemic state could be established as self-reported diabetes or incident- or no diabetes by means 
of FPG during the study visit were included in the analysis.
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PopulationThe inclusion criteria were: age 18–80 years and established coronary artery disease 
defined as hospitalisation for (1) elective or emergency coronary artery by-pass graft surgery (CABG); (2) percutaneous coronary intervention (PCI); (3) acute myocardial infarction (AMI; with or without ST elevation) or (4) acute myocardial ischemia without 
evidence of infarction (troponin negative), ≥6 but <36 months before the interview. The 
median time between the index event and interview was 1.2 years (IQR 1.0–1.8). The patients were divided into three groups based on glycaemic state: prevalent-, incident- 
and no diabetes. Prevalent diabetes was defined as self reported diabetes diagnosed 
by a physician. The diagnosis of incident diabetes was based on a fasting glucose of >7 
mmol/L (>126 mg/dl) at the time of the interview. 
Identification & Study visit
Patients were identified from diagnostic registries, hospital discharge lists or other valid 
sources and contacted by phone or mail. Trained research staff reviewed the medical records, interviewed and examined the patients and entered the data into an electronic 
central database. Demographic details, anthropometrics, blood samples, self reported lifestyle and medication were obtained during an outpatient visit at the participating 
centres. Data collectors were trained to use standardised methodologies for physical 
measurements. All equipment was calibrated according to the manufacturer’s 
recommendations.
Investigations
Blood lipids and plasma glucose were measured in the fasting state. Total- and HDL-cholesterol, triglycerides in serum were analysed while low LDL-cholesterol was 
calculated according the formula by Friedewald.117 Plasma glucose was analysed in all 
patients and HbA1c in those with self reported diabetes. All laboratory investigations were performed at a central laboratory (Disease Risk Unit, National Institute for Health 
and Welfare, Helsinki, Finland).
Table 8. Treatment targets according to the European Guidelines on Cardiovascular Disease 
Prevention in clinical practice issued 2003115, and updated in 201249  and the European Guidelines 
for Diabetes, Pre-Diabetes and Cardiovascular Disease issued 2007116, and updated in 201317. The 
targets from 2003, 2007 and 2012 where used analysing the results in Study III and 2007, 2012 and 
2013 in IV.
                                                                                                                Guideline
 Variable Prevention 2003
Diabetes 
2007
Prevention 
2012
Diabetes 
2013
Blood pressure (mm Hg) 
(no diabetes) <140/90 <140/90 <140/90 <140/90 
Blood pressure (mm Hg) 
(diabetes) <130/80 <130/80 < 140/80 <140/85 
LDL-cholesterol mmol/L (mg/dl) 
(no diabetes and diabetes) ≤2.5 (≤ 100) ≤1.8 (≤ 70) ≤1.8 (≤ 70) ≤1.8 (≤ 70)
HbA1c % (mmol/mol)
(diabetes) ≤6.1% (≤ 48) ≤6.5% (≤ 48) ≤7.0% (≤ 53) ≤7.0% (≤ 53)
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Height and weight were measured in light indoor clothes without shoes (scales 701 and 
measuring stick model 220; SECA Medical Measuring Systems and Scales, Birmingham, UK).
Blood pressure was measured twice on the right upper arm in the sitting position using 
automatic digital sphygmomanometers (Omron M5-I, Illinois, USA). 
The use of four cardioprotective drug therapies (antiplatelet drugs, β-blockers, renin-angiotensin-aldosterone-system (RAAS) blockers and statins) was assessed at the time 
for the interview. The patient was asked to bring an updated list of medications or the 
medication itself.
Health Care-Providers seen were assessed by asking the patient.
Definitions Treatment targets were those recommended in the Joint European Guidelines on Cardiovascular Disease Prevention from 2003115. Analysis was also perfromed for the 2007116 and 201249 guidelines as presented in Table 8. 
Data managementThe database was kept at the ESC Euro Heart Survey Department at the European Heart 
House (Sophia Antipolis, France). Data were collected electronically using a unique 
identification number for country, centre and individual. All data were stored under the 
provisions of National Data Protection Regulations.
Statistical analysisThe statistical analyses were performed at the Department of Public Health, University 
of Ghent in Belgium by means of SAS statistical software release 9.1 (SAS Institute 
Inc., Cary, North Carolina, USA). Descriptive statistics (means, standard deviation 
and proportions) were used to present information on patient characteristics. The distribution of patient characteristics across groups (Table 11) was compared 
according to the Chi-square test. Use of pharmacological treatments, proportions of patients reaching treatment targets for blood pressure, LDL-cholesterol and HbA1c and healthcare providers (Table 12-13, Figure 17-19) were compared between groups according to multilevel logistic modelling118 accounting for clustering of patients within centres and in addition adjusting for potential confounding due to differences in 
distributions of age and sex. A p-level of <0.05 was a accepted as statistically significant.
Ethical considerationsNational coordinators obtained approvals from Local Research Ethics Committees and 
all participants signed a consent form following oral and written information.
Studies IV and V
Aim
Study IV - To investigate if patients with coronary artery disease, with and without diabetes, are managed according to recommendations given in European Practice Guidelines from 2007116, 201249 and 201317 as presented in Table 8.
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Study V - To determine which screening test has the best capacity to detect dysglycaemia 
in patients with coronary artery disease.
Design
Studies IV and V are based on data from the study EUROASPIRE IV, an observational, cross sectional survey conducted at 79 centres in 24 European countries between 2012-
2013, interviewing and investigating patients with established coronary artery disease. The study was a fusion of the protocols from Study III and the Euro Heart Survey of Diabetes and the Heart62. A total of 16 426 medical records were scrutinised in the 
search for study participants and 7998 (49%) attended the interview. 
Study IV comprised all patients in whom the glycaemic state could be established as prevalent-, incident- or no diabetes by means of FPG, 2hPG or HbA1 during the study 
visit. Full information on the glycaemic state was available in 6187 (77%) of the participants of whom 2846 (46%) had no diabetes, 1158 (19%) incident diabetes and 
2183 (35%) prevalent diabetes.
Study V included patients without prevalent diabetes in whom full information on FPG, 
OGTT and HbA1c was available (n=4004). 
PopulationThe inclusion criteria were the same as for Study III. The median time between index 
event and interview was 1.35 years (interquartile range 0.95-1.93 years). 
Identification & Study visitWere the same as for Study III.                                                                                                                     
Investigations
HbA1c and blood lipids were measured similarily as in Study III, with the difference that 
HbA1c was collected in all patients.An OGTT was performed using 75 grams of glucose in 200 ml of water in the 
morning after at least 10 hours of fasting. Plasma glucose was analysed locally with a photometric point-of-care technique (Glucose 201, HemoCue®, Ängelholm, Sweden). Regression analysis between the HemoCue® instrument and standard isotope dilution 
gas chromatography–mass spectrometry (IDGC-MS) showed a slope of 1.051 (95% 
confidence interval: 1.031–1.071) an intercept of -0.222 (95% CI -0.016 - -0.428; r 
= 0.994). The mean deviation was 0.24 mmol/L (2.0%). Values obtained with the HemoCue® instrument were in 69% within 5%, in 91% within 10%, and within 14,3% 
of the IDGC-MS method.119 The HemoCue® method is cholesterol-sensitive due to the measurement in very small volumes resulting in higher levels of glycaemia with a lower cholesterol; therefore the glucose values were corrected for cholesterol according to the formula: HemoCue® glucose + 0.22 x (total cholesterol -5). Before final data analysis the values were converted from whole venous blood to plasma applying the formula established by Carstensen et al120 : plasma glucose = 0.558 + 0.119 x whole blood glucose, as used by the DECODE study group121 and in the Euro Heart Survey on Diabetes and the Heart63. Proper use of the equipment was assured through central training of the 
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data collectors, and retrieval of HemoCue®-cuvette storage information and validation 
sheets from a selection of the participating centres.
Height, weight and use of cardioprotective drug therapies were assessed in the same way as in Study III at study visit. 
Blood pressure was measured in the same way as Study III but using the Omron M6; 
OMRON Corporation, Kyoto, Japan. 
Waist circumference was measured using a metal tape applied horizontally at the point midway in the mid-axillary line between the lowest rim of the rib cage and the tip of the 
hip bone (superior iliac crest) with the patient standing.122
Definitions
Dysglycaemia was defined according to Table 1:When the term ‘high risk for diabetes’ is used it includes IFG and IGT according to 
WHO’s criteria or IFG and high risk HbA1c according to ADA’s criteria.
Smoking at the time of interview was defined as self-reported smoking, and/or a breath 
carbon monoxide exceeding 10 ppm.123
Physical activity was assessed by international activity questionnaire (IPAQ). Low 
physical activity was defined as less than “moderate or vigorous physical activity for at 
least twenty minutes more than once/week”.124
Low educational level was defined as primary school completed or less.
Data managementWas the same as for Study III.
Statistical analysis
Study IV Was the same as for Study III but was, in addition to age and gender corrected for BMI 
and waits circumference.
Study VDescriptive statistics (means, standard deviation and proportions) were used to 
present information on patient characteristics. Included and excluded patients were 
compared according to Fisher’s exact test and the Mann-Whitney U test. P-values for the comparison between the three separate exclusive groups were obtained by means 
of logistic regression analysis adjusting for gender and age at interview. A double sided 
p <0.05 was considered statistically significant. All statistical analyses were undertaken 
using SAS statistical software release 9.3 (SAS Institute Inc., Cary, North Carolina, USA).
Ethical considerationsLocal ethics committees of all participating centres approved EUROASPIRE IV (In 
Sweden Dnr: 2011/1929-31/3). Written, informed consent was obtained from each 
participant. All data were introduced into the electronic database with the study number. 
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RESULTS
Study IThe total response rate was 69% varying from 81% from the cardiologists to 57% from 
public health institutes. The northern parts of Europe responded more frequently (85 %) 
than the eastern part (57%) with the western and southern parts in between (Table 9).   
Table 9. Response rate and regional division of countries. + = respons, - = no respons, o = no recipient 
identified.
Ministry of 
health Cardiologist
Public health 
institute
Patient 
representative
Total
North 81%
  Denmark + + + +
  Finland + + + +
  Iceland - + - -
  Norway + + + +
  Sweden + + + +
South 68%
  Cyprus + + o -
  Greece + + + +
  Italy + + - +
  Malta + - + o
  Portugal - + - +
  Spain - + - +
East 57%
  Bulgaria - + + o
  Croatia - - + o
  Czech Republic + + - o
  Estonia + + - -
  Hungary + - - +
  Latvia + + + o
  Lithuania - + + +
  Macedonia o - + o
  Poland - + + o
  Romania - + - o
  Slovakia - + - -
  Slovenia - - - +
  Turkey + + + +
West 77%
  Austria + - + +
  Belgium + + + +
  France - + - -
  Germany + + + +
  Ireland - + + +
  Luxembourg + + o o
  Netherlands + + - +
  United Kingdom + + - +
TOTAL 61% 81% 57% 78% 69%
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Target fulfilment of the European Heart Health Charter
The perceived proximity to the EHHC targets was on average rated as five out of the 
maximum of ten by all professional groups and regions. There were only small differences between the four geographical regions with health policy leaders from Northern Europe rating their region somewhat closer to the targets and those from Western 
Europe somewhat further away. Health professionals and public representatives rated political initiatives as the type of action most needed to improve cardiovascular health 
while health politicians and public health officials rated improved organisation as 
most important (Figure 12). The northern region rated slightly higher on lifestyle and 
attitude and lower on economic factors compared to the other regions. 
Figure 13 presents countrywide comparisons of the perceived proximity to the EHHC target of normoglycaemia, expressed as the average response from all leaders and the actual prevalence of diabetes obtained through the Euro Heart Survey cardiovascular statistics 2006113. A similar perception of the national situation in two countries did not 
mean that the actual situation observed was the same. There were small differences between the four professional groups on the perception of the extent to which the 
different types of measures were used. The measure believed to be used to the largest extent was prohibition of smoking in public areas, while the subsidisation of physical activities through tax or other incentives at a corporate level was believed to be used 
the least. One finding was a discrepancy between the perception of the use of a measure 
and its actual implementation. For instance a difference could be observed between the perceived use of public smoking bans and the actual existence of public smoking bans at a national level125 as presented in Figure 14. 
Figure 12. Predefined factors (as described in Table 5) rated as important obstacles (Panel A + C) or 
actions required (Panel B + D) to improve cardiovascular health by profession (A + B) and region (C + 
D). Y-axis 3 = most important; 2 = second most important; 1 = third most important; 0 = not among 
the three most important.
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Study II
Response RateThe response rate for the Webb-QPS-FINDRISC questionnaire is summarised in Figure 
15. The group was composed of 10% doctors, 67% nurses, 7% medical secretaries and 
16% other hospital staff, it was a similar distribution in non-responders to FINDRISC. Of those responding 3029 (84%) replied to one or more questions in the FINDRISC 
section, which is 59% of the original population. A total of 1948 (54%) completed 
the entire FINDRISC. Apart from age (100%) the response rate was similar for all 
the questions (82-93%) (Figure 15). If a study participant had an incomplete answer 
to FINDRISC, usually only one question was omitted. Individuals with self-reported 
diabetes, 1.6% of the population answering to Webb-QPS, were excluded from the 
analysis.
3-4
5-6
>9
7-8
<2
No data
PERCIEVED NORMAL 
GLUCOSE METABOLISM
Score
PERC IVED NOR AL 
GLUCOMETABOLISM
DIABETES, AGE 20-79
7 to 9
5 to 7
< 5 
> 9
No data
Percentage
DIABETES, AGE 20-79
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    < 5
    5 to 7
    7 to 9
    > 9
    No dat
Figure 13. Perceived national proximity to the EHHC goal of normal glucometabolism (1= far away, 
10 = on target) juxtaposed to the actual prevalence of diabetes in adults retrieved from the Euro 
Heart Survey Cardiovascular statistics 2006113. 
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Figure 14. Perceived use of the prohibition of smoking in public areas (left panel) compared to the 
actual existence of smoking bans (right panel) retrieved from the European Commission125. In the 
right panel yellow indicates total protection in all enclosed workplaces and public places (smok-
ing banned all together), orange indicates comprehensive protection (smoking allowed in separate 
smoking rooms), red indicates partial protection (smoking allowed in certain categories of venues, 
e.g. parts of the hospitality sector).
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Risk groups identifiedStudy participants belonging to different risk groups were distributed as outlined in 
Table 10 and Figure 16 regarding numbers and gender. The risk score predicts that 
298 (9.8%, 8.6% women, 10.0% men) of the participants in Webb-QPS are likely to have diabetes if tested with an OGTT or will develop diabetes over the coming decade if 
no intervention is initiated. Individuals who are considered to benefit from preventive interventions are those at moderate (n = 828), high (n = 196) and very high (n = 58) risk (total group n = 1028; 19.8%). When the average answer from individuals with complete and incomplete FINDRISC are compared, those with complete answers seem 
to present a slightly higher risk profile.  There was no data avaliable on non-responders 
to Webb-QPS.
Study III
A total of 13 935 medical records were reviewed and 8966 (64%) patients interviewed. The present study population comprises 6588, 74% of those interviewed, with available 
information on their glycaemic state.  In the study population 65% had no diabetes, 11% 
incident diabetes and 23% prevalent diabetes. Patient characteristics are presented in 
Table 11. 
Table 10. Identified risk groups.
Risk group Low Slightly elevated Moderate High Very high
Total % (n) 16 (481) 48 (1466) 27 (828) 7 (196) 2 (58)
Women % (n) 16 (421) 48 (1271) 28 (732) 7 (180) 2 (54)
Men % (n) 16 (60) 53 (195) 26 (96) 4 (16) 1 (4)
Figure 15. Response rate to Webb-QPS and FINDRISC.
Distributed Webb-QPS
n = 5166 [100%] (W: 87%, A: 44)
Webb-QPS answer 
n = 3581 [69%] (W: 88%, A: 44.5)
Webb-QPS no answer 
n = 1585 [31%] (W: 86%, A: 42)
FINDRISC no answer
n = 552 [16%]
FINDRISC incomplete
n = 1081  [30%]
Q1 100% Q2 82% Q3 84% Q4 89% Q5 93%, Q6 89% Q7 92% Q8 93%
FINDRISC complete
n = 1948 [54%]
Q1 = age, Q2 = BMI, Q3 = waist circumference, Q4 = physical activity, Q5 = vegetables, 
Q6 = blood pressure lowering, Q7 = high blood glucose, Q8 = heredity. Group characteristics in 
brackets: W = % Women, A = average age.
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Table 11. Patient characteristics. Data presented are % with number of patients in brackets if not 
stated otherwise.
Variable Diabetes P-value1
No Incident Prevalent
n= 4295 n= 752 n= 1541
Age P<0.0001
   < 50 years 12 (510/4295) 7 (52/752) 6 (86/1541)
   50–59 years 28 (1198/4295) 29 (218/752) 26 (406/1541)
   60–69 years 36 (1550/4295) 39 (292/752) 41 (625/1541)
   >70 years 24 (1037/4295) 25 (190/752) 28 (424/1541)
Sex P<0.0001
   Women 24 (1008/4295) 21 (159/752) 30 (469/1541)
   Men 77 (3287/4295) 79 (593/752) 70 (1072/1541)
Inclusion event P=0.0002
   CABG2 18 (789/4295) 17 (128/752) 23 (360/1541)
   PCI3 45 (1926/4295) 42 (319/752) 42 (639/1541)
   AMI4 20 (874/4295) 21 (158/752) 19 (290/1541)
   Ischemia 16 (706/4295) 20 (147/752) 16 (252/1541)
AMI ever5 65 (2788/4293) 65 (488/752) 64 (988/1541) P=0.84
Non smoker 82 (3525/4289) 83 (619/750) 87 (1330/1538) P=0.0005
BMI6, kg/m2 P<0.0001
   <25 22 (934/4278) 14 (101/750) 12 (176/1528)
   25 - 29.9 50 (2119/4278) 44 (329/750) 41 (633/1528)
   ≥30 29 (1225/4278) 43 (320/750) 47 (719/1528)
1 Significance of differences between the groups, 2 CABG = Coronary Artery By-pass Graft, 3 PCI = Percutaneous Coronary 
Intervention,4AMI = Acute Myocardial Infarction, 5 Composite of AMI as an index event, CABG or PCI as an index event because 
of AMI (information from medical records) and self reported AMI (information at interview)., 6 BMI = Body Mass Index
Figure 16. Number (left y-axis) and percentage (right y-axis) of individuals at the Karolinska University 
Hospital divided into risk groups for diabetes. The number predicted to develop diabetes the upcoming 
ten years are indicated by the light gray part of the bar and by the numbers in brackets below each risk 
group. The risk groups are defined as follows: low = estimated 1 in 100 will develop diabetes, slightly 
elevated = estimated 1 in 25 will develop diabetes, moderate = estimated 1 in 6 will develop diabetes, 
high = estimated 1 in 3 will develop diabetes, very high = estimated 1 in 2 will develop diabetes.
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The use of the four cardioprotective drug therapies is described in Table 12. In all three 
groups >97% of the patients reported that they never or seldom missed or altered their 
medication. Figure 17 shows the proportion of patients reaching three selected blood pressure target 
levels. Half of the patients with no diabetes and one fifth of those with prevalent diabetes 
reached the recommended blood pressure target of <140/90 mmHg and <130/80 mmHg respectively as recommended in 
the 2007 Prevention Guidelines. When applying a blood pressure target of 
<140/80 mmHg as recommended in the 2012 prevention guidelines49 28% of the patients with prevalent diabetes reached 
the target. Figure 18 shows the proportion of patients reaching three different LDL-
cholesterol levels. Forty-four per cent of the patients with no diabetes, 40% of those with incident diabetes and 53% with prevalent diabetes reached the treatment target for LDL-cholesterol of 
<2.5 mmol/l (<97 mg/dL).Out of the patients with prevalent diabetes 22% reached the guideline 
treatment target of HbA1c <6.1% (<43 
mmol/mol) as shown in Figure 19. When 
Table 12. Use of pharmacological therapy in % (n/total n). 
Ongoing therapy
Diabetes
No Incident Prevalent P-value1
Aspirin or other 
antiplatelet agents
91 (3902/4284) 93 (693/749) 91 (1400/1533) P=0.34
β-blockers 79 (3391/4279) 84 (631/750) 81 (1243/1533) P=0.01
   Whereof β-blockers in  
   patients with AMI2 ever
81 (2263/2788) 86 (420/488) 84 (826/988) P=0.02
RAAS-blockers3 68 (2919/4277) 76 (567/749) 77 (1180/1532) P<0.0001
   Whereof ACEi4 59 (2525/4277) 67 (500/749) 62 (951/1532) P<0.0001
Statins 79 (3385/4275) 80 (597/750) 80 (1230/1533) P=0.72
All of the above5 44 (1865/4271) 51 (384/749) 50 (766/1530) P<0.0001
Glucose lowering
   Oral - - 60 (916/1534) 
   Insulin - - 24 (369/1520) 
1Taking into account clustering of patients within centres and adjusted for age and sex 2 Acute Myocardial Infarction
3Renin-Angiotensin-Aldosterone-blockers including Angiotensin Converting Enzyme inhibitors and Angiotensin 
Receptor Blockers 4Angiotensin Converting Enzyme inhibitors 5 The combination of aspirin or other antiplatelet, 
β-blocker, RAAS-blocker and statins.
Figure 17. Percentage of patients reaching blood 
pressure treatment target by diabetes state (no, 
incident, prevalent) accounting for clustering of 
patients within centres and adjusted for age and 
sex. White: <130/80 mmHg (differences between 
groups p<0.005). Grey: <140/90 mmHg (differ-
ences between groups p<0.0001). Black: <150/100 
mmHg (differences between groups p<0.0001).
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asked about access to healthcare providers 17% of the patients with prevalent diabetes 
reported being seen by an endocrinologist/diabetologist. A majority of the patients 
went to multiple healthcare providers as presented in Table 13.
Study IV
Clinical characteristics are presented in Table 14. Those with incident and prevalent 
diabetes were older and more obese. Patients with prevalent diabetes were least 
physically active. 
The use of antiplatelet agents (primarily aspirin), β-blockers, RAAS-blockers and statins 
are presented in Table 15. The highest proportion of patients prescribed a combination 
of the four drugs was in those with prevalent diabetes. 
Figure 18. Percentage of patients reaching LDL-
cholesterol treatment target by diabetes state (no, 
incident and prevalent) accounting for clustering 
of patients within centres and adjusted for age 
and sex. White: LDL-cholesterol <1.8 mmol/L (<70 
mg/dL) (differences between groups p<0.0001). 
Grey: LDL-cholesterol <2.5 mmol/L (<97 mg/dL) 
(differences between groups p<0.0001). Black:   
LDL-cholesterol <3.0 mmol/L (<116 mg/dL) (differ-
ences between groups p=0.0002). 
Figure 19. Percentage of diabetes patients reach-
ing HbA1c (DCCT) treatment targets accounting for 
clustering of patients within centres and adjusted 
for age and sex. Striped: HbA1c <6.1% mmol/L 
(<43 mmol/mol). White: HbA1c <6.5% mmol/L 
(<48 mmol/mol). Grey: HbA1c <7.0 mmol/L (<53 
mmol/mol). Black <8.0 mmol/L (<64 mmol/mol).
Table 13. Health-care provider providing the care presented as % (n/total n).
Health-care provider
Diabetes
No Incident Prevalent P-value1
General practitioner 53 (2285/4290) 51 (383/752) 51 (775/1536) P=0.66
Cardiologist 70 (3016/4290) 75 (561/752) 73 (1121/1536) P=0.68
Endocrinologist/Diabetologist 1 (47/4290) 1 (8/752) 17 (267/1536) P<0.0001
Cardiac specialist nurse 2 (80/4290) 1 (9/752) 2 (23/1536) P=0.86
Cardiac rehabilitation program 35 (1504/4247) 33 (248/748) 32 (486/1522) P=0.48
1Taking into account clustering of patients within centres and adjusted for age and sex.
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Table 14.  Patient characteristics of the 6187 included and 1811 excluded patients. Data presented 
are % (n/total n) if not stated otherwise. 
Variable
Diabetes P-value1
Missing infoNo Incident Prevalent
Participants 46 (2846/6187) 19 (1158/6187) 35 (2183/6187) 1811
Age (years)
   Mean (±SD) 63 (10.0) 65 (9.2) 65 (8.6) <0.0001 64 (9.6)
   < 50 11 (320/2846) 6 (68/1158) 5 (102/2183) 11 (191/1811)
   50–59 25 (714/2846) 23 (263/1158) 21 (451/2183) 27 (492/1811)
   60–69 36 (1026/2846) 38 (437/1158) 41 (900/2183) 34 (622/1811)
   >70 28 (786/2846) 34 (390/1158) 33 (730/2183) 28 (506/1811)
Sex 0.006                  
   Women 24 (674/2846) 23 (268/1158) 27 (594/2183) 23 (412/1811)
   Men 76 (2172/2846) 77 (890/1158) 73 (1589/2183) 77 (1399/1811)
Inclusion event 0.002                  
   CABG2 11 (304/2846) 12 (143/1158) 14 (315/2183) 15 (262/1811)
   PCI3 55 (1576/2846) 53 (619/1158) 52 (1143/2183) 54 (983/1811)
   AMI4 24 (671/2846) 24 (273/1158) 21 (468/2183) 23 (414/1811)
   Ischemia 10 (295/2846) 11 (123/1158) 12 (257/2183) 8 (152/1811)
AMI ever5 66 (1888/2842) 65 (753/1158) 65 (1407/2178) 0.37 67(1214/1809)
Smoker 16 (464/2846) 14 (165/1158) 14 (304/2183) 0.04 19 (346/1811)
BMI6, kg/m2 28 (4.2) 29 (4.5) 31 (5.0) <0.0001 29 (4.7)
   <25 23 (638/2841) 14 (164/1158) 11 (239/2171) 21 (384/1792)
   >25 – 29.9 48 (1349/2841) 46 (533/1158) 39 (846/2171) 46(818/1792)
   ≥30 30 (854/2841) 40 (461/1158) 50 (1086/2171) 33 (590/1792)
Central Obesity 51 (1439/2806) 63 (724/1146) 71 (1510/2135) <0.0001 51 (895/1768)
Low physical activity 60 (1591/2647) 60 (643/1069) 69 (1318/1904) <0.0001 58 (914/1581)
FPG (mean + SD) 6.0 (0.6) 7.3 (0.9) 8.6 (2.9) <0.0001 6.1 (1.7)
2hPG (mean + SD) 7.1 (1.7) 10.1 (3.4) -- <0.0001 --
HbA1c (mean + SD) 5.6 (0.3) 6.0 (0.6) 7.2 (1.4) <0.0001 5.8 (0.7)
1 Significance of differences between the groups, 2 CABG = Coronary Artery By-pass Graft, 3 PCI = Percutaneous Coronary 
Intervention,4AMI = Acute Myocardial Infarction, 5 Composite of AMI as an index event, CABG or PCI as an index event because 
of AMI (information from medical records) and self reported AMI (information at interview)., 6 BMI = Body Mass Index
Table 15. Use of cardioprotective pharmacological therapy in % (n/total n). 
Ongoing therapy
Diabetes
No Incident Prevalent P-value1
ASA or other anticoagulants 94 (2655/2834) 92 (1064/1154) 94 (2046/2172) 0.23
β-blockers 81 (2301/2834) 83 (961/1154) 86 (1873/2172) <0.0001
Whereof in patients with AMI2 
ever
83 (1571/1879) 85 (639/750) 88(1223/1398) 0.004
RAAS-blockers3 73 (2064/2834) 77 (883/1154) 80 (1727/2172) <0.0001
ACEi4 58 (1637/2834) 61 (698/1154) 59 (1280/2172) 0.89
Statins 85 (2409/2894) 85 (982/1154) 87 (1880/2172) 0.61
All of the above5 53 (1501/2894) 55 (634/1154) 60 (1295/2172) <0.0001
1Taking into account clustering of patients within centres and adjusted for age and sex 2Acute Myocardial Infarction
3Renin-Angiotensin-Aldosterone-blockers including Angiotensin Converting Enzyme inhibitors and Angiotensin Receptor Blockers 
4Angiotensin Converting Enzyme inhibitors 5 The combination of aspirin or other antiplatelet, β-blocker, RAAS-blocker and statins.
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Dietary treatment was used in 65% of the patients with prevalent diabetes. The most commonly used glucose lowering drugs in patients with prevalent diabetes were 
metformin (57%), insulin (27%), sulfonylurea (25%) and sitagliptin (6%). The most common combinations of glucose lowering drugs were metformin + sulfonylurea (15%) and metformin + insulin (11%). 
In all three groups >97% of the patients reported that they never or seldom missed or altered their medication, the same result obtained in Study III. Patients with no-, incident- and prevalent diabetes reached a blood pressure target of 140/90mmHg in 68, 61 and 54%, a target of 140/85 mmHg in 63, 56, 49% and a target 
of 130/80 mmHg in 40%, 32% and 26%. The distribution of systolic blood pressure 
levels in the three patient groups are presented in Figure 20 panel A. Patients with no diabetes had the lowest systolic blood pressure levels and those with prevalent diabetes 
the highest. Differences in diastolic pressure was less apparent (Figure 20 panel B). 
Moreover 15% of patients with no diabetes had a systolic blood pressure >150 mm Hg. The corresponding proportions for patients with incident and prevalent diabetes were 
21 and 24 % respectively.
Patients with no-, incident- and prevalent diabetes reached a LDL-cholesterol target 
of 1.8 mmol/L (70 mg/dL) in 16, 18 and 28% respectively.  Patients with prevalent 
diabetes had a better control of LDL-cholesterol than the two other groups (Figure 21). Twenty six per cent of the patients with no- and incident diabetes and 17% of those 
with prevalent diabetes had a LDL-cholesterol >3.0 mmol/l (>116 mg/dL). The total 
cholesterol <4.5 mmol/L (<174 mg/dL) was reached in 59, 59, 68% respectively.
Glycaemic control expressed as the level of HbA1c is depicted in Figure 22. Patients 
with incident- and prevalent diabetes reached an HbA1c <7.0% (53 mmol/L) in 95% 
and 53% respectively. The proportion of patients with prevalent diabetes that had an 
HbA1c >9.0% (>75 mmol/mol) was 11% compared to 0.2% in those with incident 
diabetes. 
Figure 20. Distribution of systolic (panel A) and diastolic (panel B) blood pressure in patients with 
no diabetes (blue), incident diabetes (red) and prevalent diabetes (green). The difference be-
tween groups is statistically significant (systolic blood pressure: p<0.0001, diastolic blood pressure: 
p=0.003) adjusted for BMI, waits circumference, age and sex. The vertical lines represent the targets 
of 140 mmHg and 90 mm Hg respectively.
A B
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An overview of healthcare providers is presented in Table 16. Patients with prevalent diabetes were more frequently seen by an endocrinologist (34%) while patients 
without diabetes more often attended a cardiac rehabilitation program (43%). Twenty 
seven per cent of the patients with prevalent diabetes attended a diabetes school.
Study VClinical characteristics at interview of those who were included and excluded in the 
present analyses are shown in Table 17. 
There were no major differences in the characteristics of patients with diabetes identified by only one of the three tests (Table 18), although those detected by HbA1c alone had 
a lower education level, a higher prevalence of obesity and were less physically active. 
Figure 21. Distribution of LDL-cholesterol in 
patients with no diabetes (blue), incident dia-
betes (red) and prevalent diabetes (green). 
The difference between groups is statistically 
significant (p<0.0001) adjusted for BMI, waits 
circumference, age and sex. The vertical line 
represent a target of 2.0 mmol/L.
Figure 22. Distribution of HbA1c in patients with 
incident diabetes (red) and prevalent diabetes 
(green). The difference between groups is sta-
tistically significant (p<0.0001) adjusted for BMI, 
waits circumference, age and sex. The vertical 
line represents a target of 7.0% (53 mmol/mol).
Table 16. Health-care provider delivering the care presented as % (n/total n).
Health-care provider
Diabetes
No Incident Prevalent P-value1
General practitioner 58 (1662/2845) 62 (717/1158) 65 (1408/2183) 0.07
Cardiologist 67 (1916/2846) 73 (848/1158) 74 (1618/2183) 0.69
Endocrinologist/Diabetologist 1 (40/2846) 2 (18/1158) 34 (731/2183) <0.0001
Cardiac specialist nurse 5 (134/2846) 3 (30/1158) 5 (114/2183) 0.001
Cardiac Rehabilitation Program 43 (1201/2824) 39 (451/1145) 36 (777/2154) <0.0001
1Taking into account clustering of patients within centres and adjusted for age and sex.
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Table 17. Pertinent characteristics at the time of interview of the patients included in the analysis 
(i.e. with Fasting Plasma Glucose (FPG), Oral Glucose Tolerance Test (OGTT) and HbA1c available) 
and those excluded (i.e. with missing FPG (n=71) and/or OGTT (1,195) and/or HbA1c (n=220). Values 
presented are % (numbers) if not stated otherwise.
Variable Patients included in 
the analysis
Patients excluded 
from the analysis*
P-value
 n = 4004 n =1391  
Age (years; mean ± SD) 63.6 (9.8) 62.9 (10.0) 0.065
   < 50 years 10 (388/4004) 10 (142/1391)  
   50–59 years 24 (977/4004) 28 (386/1391)  
   60–69 years 37 (1463/4004) 34 (478/1391)  
   >70 years 29 (1176/4004) 28 (385/1391)  
Sex   0.86
      Men 76 (3062/4004) 77 (1067/1391)  
      Women 24 (942/4004) 23 (324/1391)  
Current smokers 16 (629/4004) 19 (266/1391) 0.0032
BMI 28.6 (4.3) 28.5 (4.6) 0.59
   <25 kg/m2 20 (802/3999) 21 (295/1383)  
   25.0-29.9 kg/m2 47 (1882/3999) 46 (638/1383)  
   ≥30 kg/m2 33 (1315/3999) 33 (450/1383)  
Central Obesity** 55 (2163/3952) 51 (693/1361) 0.015
Blood pressure ≥140/90 mmHg 34 (1349/3994) 40 (552/1388) <0.0001
Laboratory values    
   Fasting plasma glucose ≥7 mmol/l 22 (867/4004) 25 (331/1320) 0.01
   HbA1c ≥6.5% 5 (193/4004) 7 (81/1100) 0.0009
   Total cholesterol ≥ 4.5 mmol/L 41 (1642/3999) 42 (473/1117) 0.45
   Triglycerides ≥ 1.7 mmol/L 30 (1199/3966) 31 (336/1090) 0.71
Pharmacological treatment    
   Aspirin/antiplatelets 93 (3719/3988) 94 (1305/1385) 0.21
   Beta-blockers 82 (3262/3988) 81 (1125/1385) 0.64
   ACE-inhibitors 59 (2335/3988) 60 (832/1385) 0.32
   AT-II receptor antagonists 16 (636/3988) 13 (178/1385) 0.0056
   Diuretics 25 (980/3988) 28 (385/1385) 0.018
   Statins 85 (3391/3988) 87 (1199/1385) 0.16
Low physical activity 60 (2234/3716) 59 (723/1223) 0.54
1Denotes patients with known diabetes and incomplete information on FPG, OGTT and HbA1c as presented in 
Figure 1. 2Denotes waist circumference of ≥ 88 cm for women and ≥ 102 cm for men.
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Table 18. Pertinent characteristics in patients with screen-detected diabetes by means of Fasting Plasma 
Glucose alone (FPG), 2 hour Postload Glucose alone (2hPG) and HbA1c alone.
Data presented are % (n) if not stated otherwise.
FPG
≥7 mmol/L 
(n=606)
HbA1c 
≥6.5% 
(n=49)
2hPG
≥11.1 mmol/L 
(n=218)
P = 1
Age (years; mean±SD)
Female gender 
Low educational level
Current smoking
BMI (kg/m2; mean±SD)
BMI ≥ 25
BMI ≥ 30 kg/m2
Central obesity
Blood pressure ≥140/90 mmHg
Total cholesterol ≥ 4.5 mmol/L
Triglycerides ≥ 1.7 mmol/L
ASA/antiplatelets
Beta-blockers
ACE-inhibitors
AT-II Receptor antagonists
Diuretics
Statins
Low physical activity 
65 (9.4)
22 (135/606)
18 (107/603)
15 (91/606)
29 (4.1)
84 (507/606)
35 (209/606)
58 (349/601)
39 (237/606)
43 (262/605)
27 (163/603)
91 (551/603)
82 (497/603)
59 (357/603)
16 (96/603)
31 (185/603)
84 (506/603)
54 (307/569)
61 (11.2)
12 (6/49)
29 (14/49)
20 (10/49)
30 (4.4)
86 (42/49)
53 (26/49)
66 (31/47)
31 (15/49)
37 (18/49)
41 (20/49)
98 (48/49)
92 (45/49)
63 (31/49)
10 (5/49)
25 (12/49)
90 (44/49)
71 (30/42)
67 (8.8)
28 (60/218)
16 (35/216)
11 (23/218)
30 (4.8)
85 (186/218)
42 (91/218)
62 (133/213)
41 (89/216)
37 (81/218)
31 (66/216)
96 (209/218)
83 (180/218)
67 (146/218)
16 (34/218)
31 (68/218)
89 (193/218)
63 (125/199)
0.03
0.18
0.06
0.35
0.006
0.78
0.01
0.31
0.52
0.24
0.12
0.03
0.26
0.07
0.67
0.83
0.16
0.01
1Significance of the difference between groups, adjusted for age and gender
The proportions screened as having diabetes using different tests and the overlaps 
between them are presented in Figure 23. Of the 1158 screened with diabetes the 
proportions identified were by FPG: 75%, 2hPG: 40%, %, HbA1c 17%, OGTT = FPG + 
2hPG: 96% and by HbA1c + FPG: 81%. There was little overlap in individuals detected by different methods and the proportion that had diabetes according to all three 
methods simultaneously was 7%, similar in men and women. Of the 466 patients with diabetes based on an elevated 2hPG a total of 218 (47%) would not have been detected 
with diabetes without the glucose load. Applying the WHO criteria, based on the OGTT (= FPG+2h-PG), a total of 1065 (27%) had normal glucose metabolism while the corresponding proportion was 420 (11%) 
according to the ADA criteria, based on FPG+HbA1c (Figure 24). Screening according 
to the ADA criteria for FPG + HbA1c identified 2643 (66%) of patients as having a ‘high 
risk for diabetes’ where IFG contributed 91% and High risk HbA1c 53%. The overlap, 
i.e. patients identified as having high risk by both tests, was 44%. The WHO criteria 
identified 1829 patients (46%) as having a ‘high risk for diabetes’ where 76% was iden-
tified by IFG and 53% by IGT with an overlap of 29%.  
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Figure 24. Patients with newly detected diabetes (yellow), high risk to develop diabetes (blue) and 
normoglycaemia (green) using different tests and criteria to define dysglycaemia. These are accord-
ing to WHO (panel A): diabetes: FPG ≥7.0 mmol/l (126 mg/dl) and/or 2hPG value ≥11.1 mmol/l (200 
mg/dl), IFG: FPG 6.1- 6.9 mmol/l  (110 - 125 mg/dl) and IGT: 2hPG 7.8-11.0 mmol/mol (140-198 mg/
dl; and according ADA (panel B): diabetes: FPG ≥7.0 mmol/l (126 mg/dl) and/or HbA1c ≥48mmol/mol 
(DCCT ≥6.5%). IFG: FPG 5.6- 6-9 mmol/l (101 – 125 mg/dl) and high risk HbA1c: HbA1c 39-47 mmol/
mol (DCCT = 5.7 – 6.4%). 
A B
Figure 23. Proportions and their overlap between screening with fasting plasma glucose (FPG=pink), 
plasma glucose 2 hours after a glucose load (2hPG=green stripes), glycated hemoglobin A1c 
(HbA1c=clear with blue line) and their combinations in patients with coronary artery disease.
Total diabetes WHO & ADA
N = 1158
HbA1c ≥ 6.5%
N=193 (17%)
FPG + HbA1c
N= 940 (81%)
2h-PG ≥ 11.1 mmol/L
Total N=466 (40%)FPG ≥ 7 mmol/L
N=867 (75%)
N=606
52%
N=37
3%
OGTT
(FPG+2hPG) 
N=1109
(96%)
N=24
2%
N=49
4%
N=83
7%
N=141
12%
N=218
19%
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GENERAL  DISCUSSION
Cardiovascular disease and diabetes are major causes of morbidity and mortality worldwide but a premature impact of these diseases is possible to postpone by 
prevention. The present thesis focuses on different levels of prevention: primordial, primary and secondary, using both population and high-risk based approaches in 
patients with cardiovascular disease and/or diabetes.
Policymakers’ perception of cardiovascular health 
The main finding in Study I was that policymakers in Europe agreed that national patterns of cardiovascular disease and its prevention are far from the targets set in the 
EHHC. A similar rating of the perceived proximity to a specific target in two countries 
did not necessarily reflect a similar national situation when compared to available 
statistics on the actual situation. The perception of the use of various measures as part of national attempts to improve cardiovascular health differed little between the four 
professional groups. However, when perceptions of the implementation of smoking bans were analysed more in detail it showed that a similarly perceived use did not 
necessarily relate to a similar utilisation, just as for the targets. Interestingly policymakers expressed diverging opinions on the most important 
measures to achieve an improved cardiovascular health. Health politicians rated political initiatives lower than the other groups, who in contrast believed that political 
actions are key for success. The implication is that some groups regretfully make 
cardiovascular health into a problem of ‘somebody else’. This kind of projection will certainly limit cooperation between different stakeholders, and a prerequisite for a successful investment in health must commence with mutual agreements on what is 
needed and how responsibility should best be shared.126, 127 All professional groups rated the attitude within the population as an important obstacle 
to overcome while media was the factor rated lowest. Considering their likely important 
role of public information this may seem surprising. An explanation can perhaps be that all groups were of the opinion that media already worked well with regards to 
health promotion and information. Another possibility is that the interviewed groups 
underestimate the importance of a systematic collaboration with media i.e. it is a underused tool by policymakers when it comes to changing attitudes, awareness and 
lifestyle in a population regarding their health. The reasons for the discrepant views between different countries and policymakers from the four organisations are probably multifactorial covering a wide range of areas, such as culture, history and politics, as well as the individual’s own interests, opinions 
and knowledge. The discrepancy between perception and statistics in Study I will likely affect the possibility of achieving a wider penetration of the preventive targets listed 
in the EHHC. If the policymakers perceived risk factors as relatively unimportant or already appropriately dealt with, they are likely less interested in adopting the charter 
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recommendations in their country. Existing variations in cardiovascular health across Europe33, with higher mortality and morbidity in eastern countries, will likely affect 
the priority of cardiovascular prevention. The findings in Study I underscore the importance of accurate epidemiological information, such as provided in Study III 
and IV, as well as knowledge of suited targets and available measures when building 
national plans to improve prevention.Research investigating political factors shaping public health is limited, and mainly 
focused on the transfer of scientific evidence into public health policy, making it hard 
to compare the present findings to other studies.108-111, 128 An on-going study, Kidney Health for Life, has been initiated using Study I as a template to organize their work (personal communication: A Levin, MD Chair, International Steering Group Kidney 
Health for Life). It is encouraging that health policy is getting more attention. Hopefully 
these two investigations will encourage further research in this important area. Increased insights in how different stakeholders experience actions and obstacles to improved health as well as knowledge on potential discrepancies in their opinion are 
fundamental in order to create consolidated health oriented programmes. Efforts from the medical profession to better understand the political process are required, as well as efforts by policymakers to be up to date with medical research, when launching 
societal endeavours aiming at shifting the risk pattern in a population.
Strengths and limitations of Study I
The small sample size of the present study makes it hard to draw definitive conclusions. Nevertheless the aim of the study was to investigate the perception of key health 
policymakers, which is likely to influence health policy. As such, the findings in Study 
I invite reflections of the importance for future population wide preventive initiatives. 
Feasibility of using FINDRISC in an online questionnaire FINDRISC incorporated in a workplace survey yielded a reasonably good response rate in Study II. This holds true not the least considering that many individuals, who would 
normally not participate in any risk assessments, were included. Studies following white-collar workers longitudinally were able to reach response rates around 85% 
to Webb-QPS (D Hassan: personal communication). The main predictors of such a high response rate include a well-orchestrated implementation procedure and a high 
involvement from the workplace managers. The estimated prevalence of diabetes in the Stockholm area is 5% for men and 3% for women,129 and about 30% of all Swedes with diabetes are considered to be 
undiscovered.129, 130 The annual incidence of diabetes in Sweden is 0.2% i.e. 2% per 
decade.131 Only a low proportion of the screened population in Study II had diabetes 
(1.6%) while the 10-year risk to develop diabetes was higher than expected (men 
8.6%; women 10%). A partial explanation may be that the targeted population in Study 
II belonged to an age-group in which diabetes starts to increase and another reason may be that more people aware of their potential risk choose to answer the FINDRISC 
questions than those who considered themselves at a low risk. Contradicting this is that the responders and non-responders to the FINDRISC part of the questionnaire had 
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similar characteristics as regards to gender, age and profession. Unfortunately there 
was no information available on those who did not answer the Webb-QPS at all. The investigated population in Study II, educated and working in the health-care sector should reasonably have a well-developed health awareness, which may have 
contributed to both positive and negative selection biases. E.g. by increasing the willingness to answer health related questions or decreasing the interest in responding 
due to an already established awareness of their own risk pattern. Hospital staff may also have easier access to health-care than the general population and thereby choose a traditional medical consultation rather than a questionnaire as a way to get health 
related information. The fact that the questionnaire was distributed at the workplace 
could have provided a barrier. Potentially some responders did not want to share this 
type of private information with their employer and colleagues. Another potential problem with web-based data collection is availability and experience in the use of 
computers. This was not a likely concern in the present group where computers are used on a daily basis as a part of work, but must be taken into account in other less 
computer friendly populations.A web-based questionnaire makes it possible to calculate and communicate the 
individual risk for diabetes immediately. This is reassuring for people at low risk while 
actions may be instituted without delay in those at a high risk as e.g. in the Finnish Type 
2 Diabetes Prevention Programme.132 Another possibility of risk characterisation of an 
entire organisation is that the employer becomes aware of a high-risk profile among 
the employees, which may stimulate specifically tailored preventive initiatives for the 
workplace. An advantage with a web-based questionnaire is that it is easy to repeat 
providing a follow up both for the individual and for the workplace. Thus the on-line use of FINDRISC may serve as a tool to address prevention on the individual as well as 
the population level.Despite the availability of a large number of screening tools for the detection of the risk 
for diabetes research on their implementation and use in all day practice is limited.133 The present study provides support for future attempts to implement FINDRISC to 
a wider audience. A recent review of implementation of diabetes risk assessment tools, including Study II, concluded that although risk scores are cheap and effective, physicians often neglect to take advantage of them and little is studied about their 
implementation.133 Perhaps a way forward would be to create technical solutions, similar to Study II, to identify individuals and even populations at risk outside the 
traditional health care system.134 This could relieve the traditional care from working 
with screening and only direct individuals with increased risk to see a physician.
Strengths and limitations of Study II
To our knowledge this the first time FINDRISC has been used as a web-based screening 
tool.133 The large number of individuals participating in the present survey shows that 
FINDRISC is possible to implement on a larger scale. To further consolidate this finding it would be of interest to make similar web-based screenings in populations outside the 
health care sector. A weakness is the lack of information on the non-responders to the 
Webb-QPS. 
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Management of patients with coronary artery disease and diabetesA large proportion of the patients in Studies III and IV are far from the guideline 
treatment targets for blood pressure, LDL-cholesterol and HbA1c. There was some improvement comparing the outcome of Study III with that of Study IV. It was, however, less than aspired considering the European guidelines for the management of patients with diabetes, prediabetes and coronary artery disease 2007, release in between the 
two studies. A potential reason is a consistent, relatively low combined use of four 
selected cardioprotective drug therapies. Alternate explanations to the poor target achievement may relate to an incomplete dose titration of individual drugs and lack of 
patient compliance even though the patients did not report such behaviour.In Study III, conducted 2006-2007, and in Study IV, conducted 2012-2013, the combined use of antiplatelet agents (primarily aspirin), β-blockers, RAAS-blockers and statins was 50 and 60% respectively. This shows a positive trend in patients with prevalent diabetes when comparing with EUROASPIRE II135, conducted 1999-2000, 
where 23% used four or more out of eight specified drugs and the Euro Heart Survey on Diabetes and the Heart63 in 2003, where 43% used the four selected drug therapies. It is noteworthy that in Study IV patients with prevalent diabetes had the highest use of 
individual drugs, as well as their combination. Blood pressure control improved in all groups between Study III and IV and was the 
best in patients with no diabetes. Comparing proportions of patients with no-, incident- and prevalent diabetes reaching a target of 140/90 mmHg, it was 52, 49 and 43% in 
Study III increasing to 68, 61 and 54% in Study IV. Both surveys reflect that it is more 
often difficult to reach an adequate blood pressure control in patients with diabetes in whom a satisfactory control often depends on the combination of three or even four 
different classes of blood pressure lowering drugs. Even though patients with diabetes 
had the highest use of RAAS-blockers and β-blockers it seems that further drug classes need to be added or that dosages should be further titrated to reach at least a similar 
proportion at target as in the group with no diabetes.136 An important observation in Study IV is that there is a group of patients with blood pressure levels well below 
the recommended targets. Considering the J-shaped curve of blood pressure control with increasing events among coronary patients with pressures considerably and 
consistently below the recommended level this observation should induce caution.137 In Study III 12, 11 and 20% of the patients with no-, incident- and prevalent diabetes 
reached the recommended LDL-cholesterol target of <1.8 mmol/L (<70mg/dL) compared to 16, 18 and 28% in Study IV which is an improvement.138 The target 
fulfilment may possibly be better since present guidelines state that lowering of the 
LDL-cholesterol level by 50% is an alternative to a fixed target.49 The fulfilment of this particular option was unfortunately not possible to explore within the framework of the 
surveys. Even taking the slight improvement between Studies III and IV into account 
the present findings must be considered as disappointing especially for patients with diabetes, in whom an adequate blood pressure- and LDL-cholesterol control is of crucial importance as demonstrated by the STENO 2 study.30 When the investigators behind the latter study used the UKPDS risk engine based analysis of the most important contributors to the decreased morbidity and mortality in the intensively managed arm 
of the trial, lipid control was estimated to be behind 73% of the effect. The corresponding 
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proportions for blood pressure and glucose control were 11 and 13% respectively.139 Furthermore a fully developed pharmacological treatment improved one-year survival in patients with diabetes and coronary artery disease to approach the one in those free from diabetes in the Euro Heart Survey on Diabetes and the Heart.62Almost all patients with incident diabetes in Study IV were within the HbA1c goal of 
<7.0% (<53 mmol/mol), indicating that patients with a truly poor glycaemic control 
had been identified before or in proximity to their index event. Such comparison was not possible in Study III since HbA1c was only collected in patients with prevalent 
diabetes. That patients with newly diagnosed diabetes had a relatively low HbA1c is probably explained by the results in Study V in which HbA1c used alone turned out to 
be very blunt as a diagnostic test. Never the less the number of patients in Study III, IV 
and V with newly detected diabetes indicates that a sizeable proportion of such patients 
remained undiagnosed during the 6–36 months after their index coronary event. Glycaemic control in patients with prevalent diabetes had not changed much since 
Study III in which 49% had an HbA1c <7.0% (53 mmol/L) compared to 53% in Study 
IV. More alarming is that one out of ten patients with prevalent diabetes in Study IV had 
an HbA1c >9.0% (>75 mmol/mol). This must be considered unacceptable not the least 
considering the risk of microvascular complications.28, 140 An explanation to a therapeutic inertia may be recent discussions on the failure of large clinical trials attempting to 
impact macrovascular events by means of tight glycaemic control.28, 141 It must, however, be underlined that this does not mean that glucose control at a level given by present 
guidelines has become obsolete. Patients with a relatively short diabetes duration and 
without a history of cardiovascular complications are still believed to benefit from a 
more strict glycaemic control.141 Thus it is still important to care for an individually 
adapted, reasonable glycaemic control in people with diabetes.17 There was no difference between Study III and IV in the proportion of patients with a 
cardiologist as their health-care provider. General practitioners cared for more patients and patients partaking in cardiovascular rehabilitation programmes had increased 
between the two surveys. Notably, there was a two-fold increase in patients with 
prevalent diabetes taht saw an endocrinologist. It may be assumed that the higher use of 
pharmacologic treatment and improved target fulfilment seen in Study IV partly relates 
to the changing pattern of caregivers. Considering the complex nature of the combination of diabetes and coronary artery disease it is reasonable that patients with less well controlled risk factors should be referred to a specialist team with representation of all 
involved specialties. Furthermore, participation in cardiac rehabilitation and ‘diabetes schools’ have the potential to improve the personal engagement of the patients assuring 
better compliance to not the least lifestyle changes.142 Given the evidence that nurse led 
programs are achievable and efficient it is hard to understand the low proportion in 
Study III (1-2%) and in Study IV (3-5%) that were offered such care.142 Many patients were seen by multiple healthcare providers, opening for the possibility that none of them took full responsibility for a truly comprehensive management including the use 
of efficient drug combinations and a proper dose titration. Following the partially disappointing outcome of the Euro Heart Survey on Diabetes and the Heart63, the European Society of Cardiology and European Association for the Study of Diabetes joined efforts in 2007 issuing practice guidelines for patients with 
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Diabetes, Prediabetes and Cardiovascular disease.116 The comparison between Study 
III, reflecting all day practice before 2007, and Study IV, conducted five to six years after the release of the guidelines, can therefore be seen as a measure of the impact of 
such guidelines. It is reasonable to say that the improvement seen between the surveys relates to the educational efforts made in association of the distribution of the European 
preventive and diabetes guidelines. This assumption gains support by an evaluation of the distribution and use of the guidelines conducted as part of the EuroHeart II 
project supported by the European Commission. It revealed that 21 National Cardiac 
Societies across Europe had endorsed the guidelines. The guidelines has of today been downloaded 34 787 times from the ESC web portal, in addition 5000 paper copies 
and 7500 pocket guidelines were distributed by the ESC.143 Based on e-surveys among different networks of European physicians with an interest in prevention and diabetes (cardiologists, primary care and family physicians) it was concluded that almost nine out of ten of those asked had the guidelines at their workplace and that eight out of 10 
used them.143 These improvements show that a change is possible to achieve although it 
takes time. Still, and considering the disappointingly small improvements, it is evident that there is a great need of further efforts and new ways to distribute knowledge 
and to get it implemented. Many patients face an unnecessarily poor prognosis due 
to a less than optimal use of evidence based management. Perhaps the information gained from Study I could help to involve other policymakers to further encourage the 
implementation of the guidelines.
Strengths and limitations of study III and IV
Studies III and IV are large cross-sectional European studies, which enabled the 
investigation of a large group of well-characterized individuals with coronary artery 
disease. The methods were standardised and information was collected at a study visit 
ensuring high quality data. Methods used were at large uniform between the surveys. In 
Study IV a fusion of the Euro Heart Survey on Diabetes63 and the Heart and Study III138 
enabled a comparison over a time period just before and five years after the release of European Guidelines on the management of patients with diabetes and pre-diabetes17. 
The size of the two studies allowed statistically robust comparisons between different 
glycaemic groups. A drawback is that a large proportion of the (via hospital records) 
identified patients never attended the interview. One reason is believed to be that contemporary rules on how patients can be contacted in many countries only allow 
contact via mailed material prohibiting personal contact. Furthermore, Studies III 
and IV likely have a positive selection bias. Participating centres included university 
hospitals and specialist cardiac centres. Such centres may have a particular interest in 
cardiovascular prevention. This would, however, if anything underestimate the true 
problem. In Study III the classification of a patient as having incident diabetes was 
based on only fasting glucose. As made clear by Study V, this likely means that 27% of the patients with incident diabetes remained undetected and were included in the group with no diabetes in Study III. In Study IV, misclassification was limited by the use of a combination of FPG, 2hPG and HbA1c to allocate patients into their respective 
glycaemic category. According to present recommendations one sample of FPH, 2hPG 
or HbA1c is not sufficient for a final diagnosis of diabetes, which should be based on 
at least two measurements. This was, however, not possible due to study logistics but 
should not be of major importance for the interpretation of the results. 
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Screening for dysglycaemia in patients with coronary artery disease
The most important finding in Study V was that screening by means of an OGTT identified 
the largest number of patients with undetected diabetes.  The overlap in case-detection 
between FPG, 2hPG and HbA1c was very small. Moreover, screening with HbA1c alone 
would have left 83% of those with diabetes based on glucose criteria undetected. In 
addition, the total proportion of patients identified with diabetes and other forms of dysglycaemia varied from 90% using the ADA criteria for FPG + HbA1c, which may be an overestimation, to 73% using the WHO criteria for OGTT = FPG + 2hPG, which may 
be a more realistic estimate.
Screening with FPG alone is known to leave many patients with diabetes undetected.24, 144 Recent reports in smaller patient populations with acute coronary syndromes145, stable coronary artery disease146 or referral for coronary angiography147 reveal that a HbA1c 
≥6.5% only detects a small proportion of patients with unknown diabetes compared 
with screening based on OGTT.148-150 The present study confirms and extends these 
findings to a broader and larger population of coronary patients. In the Euro Heart Survey of Diabetes and the Heart the proportion of newly detected diabetes and IFG + IGT was 14% and 37% according to the WHO criteria144 in patients with stable coronary 
artery disease screened with OGTT. This is lower than the present 28% and 46% in 
Study V. Thus, the proportion of patients with undetected diabetes and IGT appears to 
have increased since 2003-2004. This highlights the great importance of investigating the glycaemic state of people with coronary artery disease as emphasised in the Joint 
European Guidelines for Diabetes, Prediabetes and Cardiovascular Disease.17 The 
findings in Study III, IV and V indicate that such screening is poorly practiced. One reason may be that an OGTT is considered a time-consuming test, and that it is easier 
to use HbA1c alone or in combination with FPG. Another possible interpretation is that diabetes and other forms of dysglycaemia are becoming more common over time as 
seen in the general populations.16 There was a limited overlap in the detection of dysglycaemia between the three screening 
methods. When HbA1c was combined with FPG the yield of patients with diabetes 
increased, approaching but not reaching the proportion identified by an OGTT. Moreover 
these two methods did not identify the same patient population. An important problem with the combination of HbA1c and FPG, as proposed by the ADA, is that it labeled nine 
out of ten patients as dysglycemic. The corresponding proportion was 73% applying the 
OGTT based WHO criteria. In addition an HbA1c between 5.7-6.4% (39-47 mmol/mol) 
is less predictive than FPG and 2hPG for the risk of developing diabetes.10, 151 Thus the 
proportions identified by the WHO criteria based on an OGTT compared with the ADA criteria based on HbA1c + FPG, indicate that the latter overestimates the prevalence of people at high risk for diabetes but underestimates the prevalence of previously 
undiagnosed diabetes in patients with coronary artery disease. The present results support that the WHO recommendation14 should be kept due to the significant increase 
in the prevalence of IFG with a lower cut-point. This impacts not only individuals but 
health-care providers as well. There is solid evidence for people with IGT, as detected by an OGTT, that lifestyle and pharmacologic interventions can reduce progression to 
diabetes by about 50%.17 Such evidence is not yet available for people with IFG and high 
risk HbA1c. 
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Under-diagnosing dysglycaemia would be less important if this state had little or no impact on the future prognosis of patients with coronary artery disease.26, 27, 63, 152-156 
In addition the 2hPG from an OGTT provides additive prognostic information. There is a stronger association between the 2hPG and the level of carotid intima media thickness, extent of coronary artery disease as well as cardiovascular risk according to 
the Framingham score than for FPG and HbA1c. 157, 158 In fact the relationship between FPG or HbA1c and the future risk for cardiovascular mortality is completely blunted following 
correction for post load glycaemia and other cardiovascular risk factors.95 Additionally, 
people with IGT (i.e.  diagnosed by a high 2hPG) are more prone to cardiovascular disease progression than those with IFG, while such information is limited regarding 
HbA1c.154, 159 Moreover, HbA1c between 5.7-6.4% (39-47 mmol/mol) is less sensitive 
than IFG and IGT to detect individuals with β–cell dysfunction and insulin resistance.151Over-diagnosing dysglycaemia due to low thresholds of FPG and HbA1c may have negative implications causing patient anxiety and unnecessary use of health care 
resources. Future clinical practice should evaluate potential differences in prognostic implication by the three tests used to detect previously unknown dysglycaemia in 
patients with coronary artery disease. When dysglycaemia is discovered in a patient with coronary artery disease, a clinician should be alerted to the high risk for recurrent 
coronary events and mortality. This risk can, however, be lowered, approaching that of normoglycemic patients, through multifactorial management, including lifestyle, 
pharmacotherapy and revascularization, as recommended by the current guidelines.17, 30, 49, 62, 63 Given the low yield of an isolated HbA1c it is perhaps better to abstain from this test in patients with coronary artery disease if resources are scarce, until more data supporting its value is available or algorithms intended to limit the use of OGTT are 
properly validated.149, 160
The OGTT has been criticized for high variability. This may relate to a dichotomization 
of the continuous variable plasma glucose. Wallander et al161 performed an OGTT at five 
days, three months and 12 months after an acute myocardial infarction in 122 patients. Of those who were diagnosed with diabetes at discharge from hospital, 93% were still 
classified as dysglycemic (diabetes 64%; IGT 29%) after 12 months indicating that an 
OGTT is a reliable test of dysglycaemia over time. These results were recently verified by a Spanish study that performed OGTT in patients at the occasion of PCI and repeated 
three years later.149 A way to further simplify the procedure of the OGTT might be to use point-of-care technology as used in Study V, providing immediate test results.119Finally, there are discrepancies in the views expressed in different guidelines and by 
expert groups on what levels should define a patient as being at high risk of developing 
diabetes based on FPG and HbA1c.10, 17, 98, 162 The OGTT is the only method on which there 
is an agreement on the definition of “high risk” i.e. IGT.10 There is a need for further 
research on the clinical value of the high-risk classification by FPG and HbA1c, before it is integrated into clinical practice as an evidence-based recommendation for patients 
with coronary artery disease. 
Strengths and limitations of Study V
Study V is the largest study that, to the best of our knowledge, compares the three currently recommended screening tests for dysglycaemia in patients with coronary 
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artery disease. In addition the same strengths and limitation as already discussed for 
Study IV can be applied.
Ethical considerations of screening In Study II a large population was subjected to a screening procedure. It is important to consider if opening a possibility for preventative initiatives in high risk people outweighs the worries raised by informing them on their situation and asking them to change their 
lifestyle. Another question to address is whether the recourses used are spent in the best 
health promoting way. Looking at the Wilson-Jungner criteria, screening for diabetes covers an important health problem and has been brought forward as a prioritised area 
by several organisations.52, 106 The pathophysiology of diabetes is well known and an early detection and early institution of treatment decreases or postpones the onset of 
diabetes. There are available programs within the already existing health care system 
to take care of people identified with a high risk for diabetes. An outstanding question has been whether future micro- and macrovascular disease can be prevented by a 
programme based on lifestyle interventions. Observations in this direction have been 
identified as reviewed by Paulweber et al19. These observations have recently gained strong support by long term follow up data from the randomised, prospective Chinese Da Qing study showing a reduction of serious retinopathy163 and even cardiovascular- as well as all-cause mortality20 in people with IGT subjected to a programme incorporating 
weight reduction and promotion of physical activity. These new data strongly supports 
that screening for IGT should be encouraged. The cost for the screening program, especially if performed online, is judged reasonably small in comparison with the 
potential savings by preventing disease. Participation should, however, as always in 
such circumstances be voluntary. Furthermore, and seen from a population perspective, repeated screening on a larger scale provides important epidemiological information 
on the direction of changes in important factors for public health. Potential population 
wide interventions could be commenced if the risk seems to rise in the population. Thus FINDRISC enables something as unusual as combining a high-risk approach together 
with a population wide approach if done on a larger scale.
Study V differs from an ethical point of view than Study II. This study involved screening in patients with a very high likelihood for diabetes and in whom the derived information 
has important prognostic information and implications for future management. Accordingly such screening should have high priority as indeed underlined by available 
guidelines.17 In this context an important ethical question is what test and what criteria 
to be preferred and what potential consequences it will have. The ADA criteria based 
on FPG and HbA1c classifies 90% of a coronary population as dysglycaemic without 
any available evidence that this is advantageous in terms of treatment or prognosis. Thus the label of dysglycaemia will be put on patients where the health-care system will have no evidence based treatment to offer, likely with both economic and personal 
consequences. In contrast there is evidence based information on both the prognostic 
value and benefits of prevention of patients screen detected with IGT or diabetes 
according to the WHO OGTT based criteria. Thus, based on the Wilson-Jungner criteria 
the OGTT should be the first hand choice at least until there is an agreement and 
evidence available for another test. 
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Future perspectives Cardiovascular disease and diabetes are responsible for just over half of the global 
mortality, and these diseases are expected to increase. The upsugre is due to increased 
logevity and a westernisation of the global lifestyle. Preventive efforts have proven 
effective and are believed to be the only way to curb the rapid increase of these diseases. Thus the question on how to implement what we know into clinical practice and 
population wide interventions are more important than ever. 
On a population level more knowledge on how health is formed through e.g. societal planning, culture and history is needed rather than further investments in the search 
for, nowadays, often minor improvements in cardiovascular disease management. So far only small fractions of health-care budgets have been dedicated to prevention, while a larg amount is allocated to the diagnosis and treatment of non-communicable disease 
that can be postponed but often not cured.164, 165 Importantly researchers and health care personnel should study the political arena and take action at that stage expanding 
their influence on how health care is planned and budgeted. As already underlined in this thesis it is only through population initiatives that large changes in the prevalence 
of cardiovascular disease and diabetes can be made. Accordingly such measures deserve 
much more attention than they have gotten so far. The use of web-based screening and health tools have great potential and will likely 
be more common in the near future. The concept of using screening online offers an opportunity to identify high-risk individuals as well as organisations and potentially 
also entire communities. Risk typing different parts of a region would provide a basis 
to further study how societal planning, culture and the workplaces affect our health. Furthermore, online tools provide the opportunity to give instant feedback and an interesting scenario would be to develop an online prevention program, perhaps supplemented by advice via a web-based platform for personal questions answered by 
trained personnel.To further improve and simplify guideline compliance checklists and order sets 
incorporated in electronic medical records would be interesting to study. In these systems the doctor and the patient could become automatically alerted if a target is 
not reached. Such an alerting system may activate improved management or a note in 
the patient record on why, in a specific situation, treatment can or should not be driven 
further.166 This strategy might help to decrease the impact of both doctor and patient 
inertia that is often seen in the management of cardiovascular risk factors.167Furthermore, the forms for an efficient and feasible transfer of patients from hospital to the outpatient care should be further studied in an attempt to improve their management.168 An observation from the recruitment of patients in Study IV and V 
was that the information provided in the final medical note was often incomplete and 
lacked a plan for the future care. In this perspective education, not only of the healthcare providers, but also the patients and their relatives, may serve as a tool to accomplish 
better transfer and treatment between health-care providers. Patients would be more involved in their care, taking joint responsibility and working towards the same targets 
as their health-care provider.169 Such a position is strongly supported in the most recent issue of the European Guidelines for Diabetes, Prediabetes and Cardiovascular Disease 
in which a chapter has been added on Patient Centred Care.17 
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Regarding diagnosis of diabetes there is a need from a clinical point of view to create a helpful algorithm on what glucose measures should be used when, where and in what 
order of priority. It would be helpful if cut-off levels could be identified for each measure 
where no other glucose tests are positive for diabetes. Another intriguing scenario would be to identify a level for FPG, 2hPG or HbA1c where patients with and without diabetes have an increased cardiovascular risk, in analogy with the current diagnostic 
thresholds for diabetes, which are related to retinopathy. 
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1. Policymakers in Europe perceive that we are far from the targets outlined in the European Heart Health Charter but differ on what they see as important 
obstacles and actions needed to improve cardiovascular health in their country. Their perception of national obstacles to improved cardiovascular health did not 
necessarily correspond with the actual situation. 
2. Creating a coherent knowledge base and action agenda regarding prevention among policymakers seem to be a key element in future programmes aiming at 
prevention.
3. The online questionnaire FINDRISC is a feasible way to identify high-risk 
individuals and risk-type a workplace population. 
4. Patients with coronary artery disease, with and without diabetes, are to a relatively low extent managed according to the European Practice Guidelines, 
although adherence seems to improve over time. 
5. Improved efforts must be made to increase guideline adherence, not the least in patients with a combination of cardiovascular disease and diabetes who have a 
poor prognosis.
6. An oral glucose tolerance test has the best capacity to screen-detect dysglycaemia 
in patients with coronary artery disease. 
CONCLUSIONS
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